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Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects nearly 
1% of the US population over the age of 65. While PD is primarily a sporadic disease, roughly 
10% of PD cases are due to genetic mutations, giving rise to familial forms of PD. Interestingly, 
mutations in two kinases, the leucine-rich repeat kinase 2 (LRRK2) and the PTEN-induced 
kinase 1 (PINK1), underlie two forms familial PD. Although the pathogenic mechanisms still 
remain unknown, many insights have been gained from investigating toxin insults and genetic 
mutations that cause parkinsonian phenotypes. Studies using neurotoxins and genetic mutations 
that underlie familial PD have implicated mitochondrial dysfunction in the pathogenesis of PD. 
This project sought to identify modes of neuroprotection that ameliorated the effects of LRRK2 
mutations on neuronal and mitochondrial homeostasis. The mechanism of protein kinase A 
(PKA)-mediated neuroprotection was investigated in neurotoxin and genetic models of PD. This 
study also explored the mechanisms of PINK1-mediated neuroprotection. Activation of PKA 
prevented mutant LRRK2-induced neurite shortening by suppressing autophagy through the 
phosphorylation of the autophagy protein, the microtubule-associated protein light chain 3. This 
study also found that mutant LRRK2 causes mitochondrial degradation by autophagy in the 
dendrites of neurons, which led to shortening of the dendrites. PINK1 suppressed the autophagy 
induction elicited by mutant LRRK2 and prevented the mitochondrial degradation and neurite 
shortening. Furthermore, mutant LRRK2 caused a delay in calcium clearance after neuronal 
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depolarization. This prolonged elevation in intracellular calcium caused mitochondrial 
depolarization followed by degradation. Indeed, calcium chelation or inhibition of voltage-gated 
calcium channel restored calcium homeostasis and attenuated the mitochondrial degradation and 
dendrite shortening induced by LRRK2 mutations. Finally using immunoprecipitation and 2-
dimensional gel electrophoresis, PINK1 was found to interact with and regulate the 
phosphorylation status of proteins that maintain mitochondrial polarization, energy production, 
and calcium buffering. Overall, these results indicate that autophagy modulation and restoration 
of mitochondrial homeostasis protects against mutant LRRK2. This study proposes that calcium 
imbalance, mitochondrial dysfunction, and autophagy dysregulation are early events in the 
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1.0  INTRODUCTION 
1.1 PARKINSON’S DISEASE 
James Parkinson first described Parkinson’s disease (PD) in his “An Essay on the Shaking Palsy” 
in 18171. Currently, 1% of the US population above the age of 50 has been diagnosed with PD2. 
It is the second most common neurodegenerative disease, but the most common movement 
disorder. The cardinal symptoms of PD are thought to arise from deficits in the brain regions that 
control movement; these symptoms include bradykinesia (slowness of movement) or akinesia 
(lack of movement), resting tremor, muscle stiffness, and postural instability3. While the cause of 
disease remains poorly understood, the pathological hallmark is the degeneration of 
dopaminergic neurons in the midbrain. These midbrain dopaminergic neurons project from the 
substantia nigra pars compacta to the caudate and putamen and regulate the corticothalamic 
circuits involved in movement control4. Reduction in dopaminergic neurotransmission or 
degeneration of the dopaminergic neurons is proposed to underlie disease onset and progression4.  
There is currently no cure or treatment to slow the disease progression5. Levodopa, a 
dopamine precursor, is the most efficacious treatment for the disease; however, it only alleviates 
the symptoms of PD5. While other therapies that attempt to modulate dopamine levels or to 
prevent, repair, or replace the injured/lost dopaminergic neurons are under development, none 
have proved successful5. Although loss of the neurons in the substantia nigra pars compacta is 
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the key pathological finding indicative of PD, there is evidence that other brain regions are 
affected6. For example, aberrations in the olfactory system and difficulty sleeping have been 
reported in patients, as well as the occurrence of dementia and other cognitive defects3. These 
findings suggest that PD may have more widespread effects on the brain outside of the basal 
ganglia, which could explain why previous therapies focused on the midbrain dopamine system 
have lacked efficacy. 
In order to more fully understand the disease process, studies have combined 
observations acquired from human tissue samples and animal and cell culture systems utilizing 
neurotoxin and genetic models of PD. Data gathered from these studies suggest that pathways 
that regulate mitochondrial homeostasis, intracellular calcium handling, and protein degradation 
may provide points of convergence between various models of PD and patient samples7-9.  
1.1.1 Mitochondrial Homeostasis  
Mitochondria, frequently referred to as the powerhouse of the cell, produce energy and 
biosynthetic molecules, serve as a calcium buffer, and regulate apoptotic and necrotic cell 
death10. Through the use of the glucose metabolite, pyruvate, mitochondria produce ATP using 
the electron transport chain to satisfy most of the cell’s energy requirements. The production of 
ATP relies on the proton electrochemical gradient established across the mitochondria inner 
membrane; as protons flow down their gradient into the matrix, the mitochondria utilize this 
energy to drive ATP synthesis10. This ATP production fuels many cellular processes, including 
proliferation, differentiation, many homeostasis events, and the suppression of cell death. 
Calcium homeostasis is maintained through a network of calcium channels and calcium 
binding proteins that prevent intracellular calcium overload8. Calcium enters neurons through n-
 3 
methyl-d-aspartate receptors and voltage-gated calcium channels during neuronal 
depolarization8. Intracellular calcium is then either extruded through the plasma membrane 
calcium ATPase or sequestered within the endoplasmic reticulum via the sarco/endoplasmic 
reticulum calcium ATPase8. The mitochondria serve as an additional reservoir during periods of 
elevated intracellular calcium11. Calcium is transported into the mitochondria, in part, through 
the voltage-dependent anion channel (VDAC) and the mitochondrial calcium uniporter12, 13. 
Upon entry, calcium flows into the negatively charged matrix, where it forms calcium-phosphate 
complexes that precipitate under high levels (0.2-2µM) of calcium, allowing the mitochondria to 
provide calcium buffering independent of the matrix calcium concentration11. The uptake of 
calcium slightly diminishes the electrochemical gradient, which is observed as a reduction in 
mitochondrial polarization using the mitochondrial membrane potential-dependent dye, 
TMRM11, 14. After the intracellular calcium loading has subsided, mitochondria gradually release 
calcium into the cytoplasm for extrusion to return to basal intracellular calcium levels11.  
Under extreme cases, the mitochondria can actually become completely depolarized, a 
process known as the mitochondrial permeability transition11. The formation of the mitochondria 
permeability transition pore allows for the release of proteins and ions from mitochondria, such 
as cytochrome c and calcium, which leads to apoptotic cell death15. This pore is comprised of 
VDAC, the adenine nucleotide transporter (ADT), and cyclophilin D15. Inhibition of this 
complex through small molecules or genetic manipulations prevents apoptotic cell death and 
increases the calcium buffering capacity of mitochondria11. Once the electrochemical gradient is 
depleted, mitochondria cease to respire, leading to the reduction/termination of ATP production, 
which has been associated with the induction of necrotic cell death15. With its roles in ATP 
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production and calcium buffering, the mitochondria also regulate the execution of cell death via 
apoptosis or necrosis. 
Due to the high requirement of mitochondrial function for neuronal homeostasis, it is no 
surprise that conditions that reduce mitochondrial function ultimately lead to disease. While the 
entire body is subjected to environmental or genetic stresses that could give rise to PD, the 
substantia nigra is particularly sensitive to mitochondrial stress. Dopaminergic neurons in the 
substantia nigra contain fewer mitochondria than surrounding brain regions16. This suggests that 
mitochondrial dysfunction would greatly impact these neurons, which possess a smaller network 
of mitochondria. These neurons also display a reduced calcium buffering capacity17. Together, 
the reduced mitochondrial content and the low calcium buffering capacity would make these 
cells susceptible to calcium-induced injury from the tonic calcium waves that establish the 
rhythmic firing patterns of substantia nigra dopaminergic neurons. One study found that 
substantia nigra neurons expressing high levels of the calcium binding protein, calbindin, were 
spared in PD patients, suggesting that enhanced calcium buffering may provide protection from 
disease18. Both the reduced calcium buffering and low mitochondrial content combined with 
mitochondrial toxin and genetic stresses implicate the loss of mitochondrial homeostasis or 
increased mitochondrial dysfunction as key events in PD pathogenesis. 
1.1.2 The Kinases of Parkinson’s Disease 
The genes associated with familial forms of PD encode a variety of different proteins. 
Interestingly, two genes PINK1 and LRRK2 encode the kinases: the PTEN-induced kinase 1 and 
the leucine-rich repeat kinase 2, respectively. PINK1 is a 581 amino acid protein that contains a 
mitochondrial targeting sequence, a transmembrane domain, and a kinase domain19. Mutations in 
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PINK1 have been associated with an autosomal recessive, early-onset form of PD20-23. Due to the 
recessive nature of familial PD associated with PINK1, the mutations arising in PINK1 are 
thought to produce loss of function mutants24. Indeed, loss of PINK1 results in mitochondrial 
aberrations, elevated production of reactive oxygen species, increased numbers of 
autophagosomes, decreased calcium buffering, and cell death in tissue culture25-30. Reduced 
kinase activity in a number of disease-associated mutants further supports this loss of function 
phenotype24. Although PINK1 deficiency in tissue culture recapitulates many of the findings 
reported in PD or toxin models, PINK1-/- animals fail to show neurodegeneration or behavioral 
deficits indicative of PD27, 31. This discrepancy between tissue culture and animal models may 
suggest modes of compensation or that lack of PINK1 does not fully reflect the dysfunction of 
PINK1 mutants. 
While disease-associated mutations in PINK1 were identified 7 years ago, the function of 
PINK1 and its substrates remain unknown22. Pridgeon and colleagues have identified TRAP1 as 
a potential PINK1 substrate; however, the biological function of this phosphorylation has yet to 
be determined32. In addition, to its interaction with the TNF receptor-associated protein 1 
(TRAP1), PINK1 has been shown to bind to other chaperones and Milton and Miro, which 
regulate mitochondrial trafficking33. Even though little is known about PINK1 signaling 
pathways, one robust finding is that overexpression of wild type PINK1 provides protection 
against a number of neurotoxic insults25, 32, 34. These protective effects have been attributed to its 
reduction in cytochrome c release and its role in maintaining mitochondrial homeostasis by 
regulating reactive oxygen species production, mitochondrial function, and mitochondrial 
degradation25-30, 32, 34, 35. The effects of PINK1 deficiency and PINK1 overexpression support the 
hypothesis that mitochondrial dysfunction plays a role in PD. 
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Previously RNAi against PINK1 has been shown to elicit an increase in mitochondrial 
localized ROS production and mitochondrial fragmentation25. While inhibition of mitochondrial 
fission via expression of a dominant negative Drp1 suppressed fragmentation, it did not reduce 
mitochondrial ROS production25. Interestingly, antioxidants suppressed both ROS production 
and mitochondrial fragmentation, indicating that ROS production is upstream of mitochondrial 
fragmentation and the cell death that follows36. Mitochondrial dysfunction caused by RNAi 
against PINK1 also induces autophagy, which restores mitochondrial homeostasis by degrading 
damaged mitochondria25. Inhibition of canonical autophagy via RNAi against beclin-1 or PI3K 
inhibitors exacerbated cell death caused by PINK1 deficiency25, supporting its prosurvival role in 
this model. This previous study also showed that PINK1 overexpression suppressed autophagy 
induced by the neurotoxin, 6-hydroxydopamine, suggesting that PINK1 levels regulate 
autophagy through an unknown mechanism25.  
Mutations in LRRK2, however, cause an autosomal dominant form of PD, and therefore, 
the mutations are thought to be gain of function mutations37, 38. LRRK2 encodes a multidomain 
protein that includes leucine-rich repeats, a kinase domain, a GTPase domain, an ankyrin 
domain, and a WD40 domain. Surprisingly, disease-associated mutants have not been linked to a 
single domain, but rather pathogenic mutations have been identified in each domain37, 38. 
Although some mutants are more penetrant or produce more severe phenotypes, the fact that 
mutations in any domain can cause disease suggests that LRRK2 plays a complex, multifaceted 
role in regulating neurobiology. 
Although the precise functions of LRRK2 are poorly understood, mutations perturb 
membrane trafficking pathways39-41, cytoskeletal dynamics42-44, and protein translation45, 46. 
Mutant LRRK2 elicits an increase in autophagy as well as aberrations in endocytosis39-41. In 
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neurons, there are also defects in synaptic vesicle trafficking47, 48. Since all of these events 
require microtubule networks, it is interesting to note that mutant LRRK2 also reduces 
microtubule dynamics through the direct phosphorylation of tubulin42. This would lead to more 
stabilized networks that are less capable of rearranging to provide new routes for protein and 
organelle trafficking, which would be required for development, plasticity, and cellular 
maintenance. LRRK2 also phosphorylates 4E-BP, which regulates protein synthesis46. Together 
these findings suggest that LRRK2 could affect neuronal maintenance through its effects on 
biosynthesis and trafficking of proteins and organelles.  
A previous study found that expression of mutant LRRK2 elicits an increase in 
autophagosomes and a decrease in neurite length41. Inhibition of autophagy prevented the neurite 
shortening induced by mutant LRRK2, whereas autophagy induction with rapamycin 
exacerbated the neurite shortening41. Interestingly, PI3K inhibitors, which inhibit canonical 
autophagy, did not suppress the mutant LRRK2 induced autophagy41. However, inhibition of the 
MAPK signaling pathway using a MEK inhibitor reduced the number of autophagosomes and 
provided protection against neurite shortening41. This study indicates that mutant LRRK2 elicits 
a non-canonical autophagy-mediated neurite retraction. 
1.2 AUTOPHAGY 
Neuronal maintenance and mitochondrial homeostasis are two overarching themes for PD that 
are regulated by biosynthetic and degradation pathways. Autophagy is a highly orchestrated 
intracellular degradation pathway through which cytoplasmic components are trafficked to the 
lysosome for degradation49. Sam Clark, Jr. first discovered this highly conserved pathway in 
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1957 during normal kidney development50. Since its initial discovery, various forms of 
autophagy have been observed in all eukaryotic model organisms including: yeast, worms, flies, 
rodents, plants, and humans49. Such strong conservation highlights the importance of this 
pathway to the health and survival of living organisms. 
Originally identified as a survival pathway utilized during times of nutrient starvation, the 
autophagy pathway has been implicated in a multitude of new roles due to immense growth in 
the research field. Similar to its function for overcoming times of nutrient deprivation, it is not 
surprising that multiple studies have implicated the autophagy pathway in longevity and healthy 
aging51. In addition to its widespread roles across the eukaryotic domain, it is no surprise that a 
function for autophagy pathway has been observed in all human tissue systems. Based on these 
findings, researchers began to investigate the effects of the autophagy pathway in human disease. 
To date, the autophagy pathway has been implicated in either a pathogenic or protective role in a 
number of neurodegenerative diseases52, cardiovascular disease53, Crohn’s and other 
gastrointestinal diseases54, innate and adaptive immunity55, and many forms of cancer56. Not 
only has autophagy been thoroughly observed in multiple roles of cellular homeostasis, but 
different types of autophagy have also been identified and characterized. 
1.2.1 Types of Autophagy 
There are currently three types of autophagy: microautophagy, chaperone-mediated autophagy, 
and macroautophagy. Microautophagy occurs when proteins or other cytoplasmic constituents 
are engulfed by lysosomal invagination52. This provides a single, direct step for protein 
degradation by the lysosome.  
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Chaperone-mediated autophagy denotes the process whereby chaperones recognize and 
deliver proteins targeted for degradation to the lysosome57. The cargo interacts with lysosomal 
receptors, which facilitate its entry into lysosomes57. Unlike micro- and macroautophagy, 
chaperone mediated autophagy is saturable due to its reliance on lysosomal receptors for protein 
entry into the lysosome. While these autophagy pathways are experimentally separable and 
differentially regulated, macroautophagy is capable of compensating for deficits in or saturation 
of chaperone-mediated autophagy58. 
Macroautophagy, which henceforth will be referred to as autophagy, is the process where 
cytoplasmic components are sequestered by double membrane-bound vesicles called 
autophagosomes. Once engulfed, the cargo is trafficked along microtubules to the lysosome, 
where the lumenal contents are degraded. In mammalian cells, the autophagy pathway can be 
separated into four steps: (1) initiation of phagophore formation, (2) sequestration of cargo 
within the autophagosome, (3) delivery of cargo to the lysosome, and (4) degradation of cargo 
and efflux of macromolecules59.  
1.2.2 The Canonical Autophagy Pathway  
Initiation is accomplished by upstream stress response and signaling pathways, which integrate 
cellular information and activate autophagy-executing proteins. Canonical autophagy induction 
is regulated by the mammalian target of rapamycin (mTOR)59. Under nutrient rich conditions, 
mTOR suppresses autophagy induction and increases protein translation59. During nutrient 
starvation, however, mTOR is inhibited and autophagy is induced as a means to produce energy. 
The inhibition of mTOR leads indirectly to the dephosphorylation of Atg13, which in its 
dephosphorylated state interacts with Atg159. This Atg13-Atg1 complex then signals through an 
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unknown mechanism to induce autophagosome formation. In addition to the mTOR-Atg1-Atg13 
signaling network, nutrient starvation also activates a class III phosphatidylinositol-3-kinase 
(PI3K)/beclin-1 complex59. The PI3K leads to increased phosphatidylinositol phosphorylation, 
which demarcates membranes for autophagosome formation60. 
Once initiated, the signal to induce autophagy is transduced to the core autophagy-
executing proteins, which include Atg3, 4, 5, 7, 8, 9, 10, 12, and 16L. To create an 
autophagosome, Atg9, the only transmembrane protein in the core machinery, localizes to 
phagophore-forming structures61. Atg12 is conjugated to Atg5 through a ubiquitin-like reaction 
via Atg 7 and 1062. The Atg5-12 conjugate interacts with Atg16L and translocates to Atg9-
positive structures. The membrane-associated Atg5-12-16L complex has been hypothesized to 
act as the E3-like enzyme in the lipid conjugation of LC3. 
Prior to its lipidation, LC3, a 147 amino acid protein, is cleaved by Atg4 at glycine-12062. 
This exposed glycine is then conjugated to a lipid moiety, most commonly 
phosphoethanolamine62. This lipidation of LC3 is catalyzed by another ubiquitin-like 
conjugation system, in which Atg3 and 7 acts like E1 and E2 ubiquitin ligases, respectively62. 
Once attached to the phagophore, LC3 regulates the extension, curvature, and closure of the 
membrane63. It also acts as a receptor for cargo via adapter proteins, including 
p62/sequestrasome 1 and NBR164, 65. Atg4 removes LC3 from the cytoplasmic surface when the 
autophagosome is complete62. 
Upon closure of the autophagosome, it traffics along microtubules to fuse with the 
lysosome49. Lysosomal acidification is necessary for fusion with the autophagosome based on 
the findings that bafilomycin A, a lysosomal ATPase inhibitor that prevents acidification, 
inhibits fusion66. Once fused, the autolysosome utilizes acid hydrolases, peptidases, and 
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proteases to digest the lumenal components from the autophagosome, as well as cargo-
recognition proteins and any LC3 on the inner membrane. Autophagic degradation is completed 
with the release of macromolecules into the cytoplasm through Atg22, the lysosomal effluxer52. 
1.2.3 Autophagy in the Nervous System 
Over the last few decades, the roles of autophagy in the nervous system have been under heavy 
investigation. Most of this work has been fueled by one of the pathological observations from 
many neurodegenerative diseases: protein aggregates. Amyotrophic lateral sclerosis, 
Alzheimer’s, Huntington’s, and Parkinson’s disease all have protein aggregates as pathological 
hallmarks59. Early research focused on the identification and use of autophagy inducers to 
degrade these aggregates. However, recent evidence suggests that excessive induction of 
autophagy has deleterious effects in the nervous system52, 59. Instead, a balance between 
autophagy induction and lysosomal degradation has been hypothesized to be a more beneficial 
therapeutic target52, 59. 
While excessive autophagy may be detrimental, deficiencies in autophagy in the nervous 
system are sufficient to cause neurodegeneration. One example is the knockout of Atg5 or Atg7 
under the nestin promoter67, 68. Both knockout mice show overt signs of neurodegeneration, 
including aggregates containing ubiquitinated proteins, neuronal cell loss, and behavioral 
abnormalities67, 68. In addition to experimental knockout of autophagy genes, a decrease in 
beclin-1, a protein involved in autophagy induction, has been observed in aged human subjects 
and Alzheimer’s disease patients69, 70. Moreover, deficits in autophagy maturation or lysosomal 
degradation have been described in lysosomal storage diseases and Alzheimer’s disease71-73. 
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Together these data indicate that deficits in autophagy may underlie certain neurodegenerative 
diseases.  
As previously mentioned, overactivation of autophagy could be as harmful as defects in 
autophagy. Mutations in LRRK2 or treatment with the neurotoxin, MPP+, elicit neuronal injury 
that requires autophagy induction40, 41, 74. In these models, autophagy inhibition is protective. One 
interesting observation from these studies is that autophagy induction in these situations is 
independent from PI3K regulation41, 74. Similar observations have also been made in non-
neuronal cells, indicating the existence of a non-canonical autophagy pathway that is activated 
under pathological conditions. Therefore, therapeutic targeting of the autophagy pathway has 
proven more a tenuous task. Rather than simply inducing or inhibiting autophagy based on 
disease states, it is important to determine the underlying reasons for the protein aggregates or 
autophagy induction, since models for the same disease often contradict each other in terms of 
autophagy regulation. 
1.3 PKA SIGNALING AND NEUROPROTECTION 
Activation of the protein kinase A signaling pathways possesses neuroprotective effects against 
PD neurotoxins75, 76. Protein kinase A (PKA) regulates many intracellular signaling pathways 
that regulate proliferation, differentiation, cellular homeostasis, and cell death. PKA is a 
holoenzyme comprised of two regulatory subunits and catalytic subunits77. Upon binding of 
cAMP to the regulatory subunits, the catalytic subunits are released to phosphorylate 
downstream targets77. The activity of PKA is regulated upstream by adenylyl cyclase, which 
catalyzes the production of cAMP from ATP, and a phosphodiesterase, which converts cAMP 
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into AMP. In addition to regulation of its activity, PKA is regulated by its localization, which is 
maintained via interactions between the regulatory subunits and A-kinase anchoring proteins 
(AKAPs)77. Previous studies have identified AKAP scaffolds linking PKA to microtubules, 
mitochondria, the endoplasmic reticulum, the nucleus, and synapses78. AKAP also binds to some 
downstream signaling molecules and regulators of PKA, thus providing a highly localized 
signaling complex78. 
In neurons, PKA has been shown to regulate neurite outgrowth and synaptic plasticity 
through transcriptional (e.g. the cAMP response element binding protein (CREB)-mediated) and 
post-translational mechanisms, such as phosphorylation of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors79, 80. Under pathological conditions, PKA provides protection 
from a numerous toxin insults, including the PD neurotoxin, 6-hydroxydopamine75. In addition 
to its anti-apoptotic effects and neurotrophic factor secretion, PKA increases mitochondrial 
function and suppresses autophagy in non-neuronal cells81-83. Overall, these studies suggest that 
PKA regulates many pathways, whose manipulation could provide therapeutic benefits for PD 
and other neurodegenerative diseases. 
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2.0  RATIONALE AND HYPOTHESES 
Proper mitochondrial function is essential for neuronal function, and mitochondrial dysfunction 
has been widely associated with neurodegenerative diseases, including PD. I hypothesize that 
mutations in LRRK2, which cause familial PD, will affect mitochondrial homeostasis. 
Autophagy has been previously shown to play an integral role in maintaining mitochondrial 
homeostasis. However, autophagy induction also mediates mutant LRRK2 induced neurite 
shortening. Since PKA is neuroprotective against 6-hydroxydopamine, a PD neurotoxin, and 
suppresses autophagy in non-neuronal cells, I hypothesize that modulation of autophagy by PKA 
will protect against mutant LRRK2 induced injury. Furthermore, I hypothesize that PINK1, a 
mitochondrial kinase that regulates mitochondrial homeostasis and calcium buffering, will 
prevent neuronal injury caused by mutant LRRK2 by preventing mutant LRRK2-elicited 
mitochondrial dysfunction. The overall hypothesis is that injury elicited by mutant LRRK2 will 
be ameliorated by restoring mitochondrial homeostasis through autophagy modulation, improved 





3.0  METHODS 
3.1 TISSUE CULTURE  
3.1.1 Mouse Cortical Neuron Isolation 
Time-pregnant mice (Hilltop Laboratory Animals, Inc., Scottdale, PA, USA) were sacrificed 
when embryos were between E14-15 by cervical dislocation. The embryos were aseptically 
removed from the uterine horns and placed in ice-cold Dulbecco’s phosphate buffered saline 
(DPBS) (Invitrogen, Carlsbad, CA, USA). The embryos were decapitated with a fresh, sterile 
scalpel, and the skull and meninges were dissected away from the brain. The cortex was isolated 
and digested with 100 units papain (Worthington Biochem. Corp. Lakewood, NJ, USA) in DPBS 
with 2-3 grains of L-cystein (Sigma-Aldrich Corp., St. Louis, MO, USA). The cells were 
triturated with fire-polished glass Pasteur Pipets (Fisher Scientific, Pittsburgh, PA, USA) and 
centrifuged at 200 x g. These steps were repeated two times to produce a single-cell suspension 
of cells. The digestion was terminated by adding 5mg/ml trypsin inhibitor (Worthington 
Biochem. Corp. Lakewood, NJ, USA), 10mM HEPES (BioWhittaker, Walkersville, MD, USA), 
5mg/ml bovine serum albumin (Fisher Scientific, Pittsburgh, PA, USA) in Dulbecco’s Modified 
Eagle Media (DMEM)/F-12 media (Invitrogen, Carlsbad, CA, USA). The cells were then plated 
on poly-lysine coated plates.  
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3.1.2 Mouse and Human Cell Culture 
Mouse cortical neurons were cultured in Neurobasal (Invitrogen, Carlsbad, CA, USA), with 
2mM Glutamax (Invitrogen, Carlsbad, CA, USA) and 2% B-27 supplement (Invitrogen, 
Carlsbad, CA, USA). Half of the media was refreshed every three days. 
Human SH-SY5Y neuroblastoma, Human Embryonic Kidney 293 (HEK 293), and 
Human Cervical Carcinoma (HeLa) cell lines were cultured in DMEM (BioWhittaker, 
Walkersville, MD, USA) with 10% fetal calf serum (BioWhittaker, Walkersville, MD, USA), 
2mM L-Glutamine (BioWhittaker, Walkersville, MD, USA), and 10mM HEPES (BioWhittaker, 
Walkersville, MD, USA). SH-SY5Y cells were differentiated with 10µM retinoic acid (Sigma-
Aldrich Corp., St. Louis, MO, USA) for 3 days prior to transfection, and remained in media 
containing retinoic acid for the duration of the experiment. All cells were maintained at 37oC 
with 5% CO2, and the media was refreshed every three days. 
All transfections were performed according to the manufacturer’s protocol using 
Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA). Briefly, Lipofectamine2000 and DNA 
plasmids or siRNA were added to separate tubes of OptiMEM (Invitrogen, Carlsbad, CA, USA) 
to incubate for 5 minutes. The OptiMEM/Lipofectamine mixture was then added to the 
DNA/siRNA. DNA/siRNA complexes with Lipofectamine were allowed to form for 15 minutes 
prior to adding the OptiMEM/Lipofectamine/DNA or siRNA mixture to the cells. The media was 
refreshed 24 hours after transfection. 
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3.1.3 Cell Culture Pharmacological Treatments 
The following drugs were administered as indicated: 10µM Forskolin (Sigma-Aldrich Corp., St. 
Louis, MO, USA), 10 µM H89 (Merck KGaA, Darmstadt, Germany), 2µM rapamycin (LC 
Laboratories, Woburn, MA, USA), 250 µM cAMP (Sigma-Aldrich Corp., St. Louis, MO, USA), 
0.5nM bafilomycin A (Merck KGaA, Darmstadt, Germany), 10nM FK506 (Enzo Life Sciences, 
Inc., Plymouth Meeting, PA, USA), 250nM okadaic acid (Merck KGaA, Darmstadt, Germany), 
2mM EGTA (Sigma-Aldrich Corp., St. Louis, MO, USA), 2µM BAPTA-AM (Invitrogen, 
Carlsbad, CA, USA), 1µM NiCl (Sigma-Aldrich Corp., St. Louis, MO, USA), 1mM MPP+ 
(Sigma-Aldrich Corp., St. Louis, MO, USA), 50nM ω-agatoxin (Tocris Bioscience, Ellisville, 
MO, USA), 100nM ω-conotoxin (Tocris Bioscience, Ellisville, MO, USA), 10µM rolipram 
(Sigma-Aldrich Corp., St. Louis, MO, USA), and 1µM nitrendipine (Tocris Bioscience, 
Ellisville, MO, USA).  
 
3.2 IMAGE ANALYSES 
3.2.1 Immunocytochemistry 
The cells were washed in phosphate buffered saline, pH 7.4 (PBS), and then incubated with 4% 
paraformaldehyde (Sigma-Aldrich Corp., St. Louis, MO, USA) in PBS for 15 minutes at room 
temperature. The cells were then washed twice with PBS and permeabilized in PBS with 0.1% 
Triton X-100 (Fisher Scientific, Pittsburgh, PA, USA) for one hour at room temperature. The 
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cells were incubated with SuperBlock (Thermo Scientific, Rockford, IL, USA) for one hour at 
room temperature to reduce non-specific antibody binding. Primary antibodies were added at the 
indicated dilutions (Table 1) for incubation overnight at 4oC. The cells were washed three times 
in PBS, and then incubated with Alexafluor-488 or -546 conjugated secondary antibodies 
(1:1000) (Invitrogen, Carlsbad, CA, USA) for one hour at room temperature. The cells were then 
washed three times with PBS and imaged on an Olympus IX71 inverted microscope. 
 
 
Table 1: Antibodies and Dilutions for Immunocytochemistry 
Antigen Dilution Company 
GFP 1:5000 Invitrogen, Carlsbad, CA, USA 
HA 1:1000 Covance, Emeryville, CA, USA 
LC3 1:500 Abgent Inc, San Diego, CA, USA 
MAP2 1:1000 Millipore, Billerica, MA, USA 
PINK1 1:2000 Invitrogen, Carlsbad, CA, USA 
TOM20 1:200 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
V5 1:1000 Invitrogen, Carlsbad, CA, USA 
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3.2.2 Neurite Length  
For neurite length analysis, SH-SY5Y cells were fixed 48 hours after transfection and imaged by 
GFP fluorescence. For cortical neurons, cells were fixed 2 weeks after transfection and stained 
for GFP and MAP2 for dendrite length analysis. Neurite length was measured using NIH ImageJ. 
3.2.3 Autophagosome Analysis  
For image-based autophagy analysis, cells were fixed and imaged for either GFP-LC3 or LC3 
immunofluorescence. The number of LC3-labeled autophagosomes was quantified per cell. LC3-
labeled autophagosomes were identified as puncta 1.5 standard deviations above the mean 
cytoplasmic intensity.  
3.2.4 Mitochondrial Content  
Mitochondrial content was measured as the mitochondrial area, as indicated by either Cox8-GFP 
or Tom20 immunofluorescence, divided by the total cytoplasmic area of the compartment. In 
cortical neurons, mitochondrial content was measured in the soma, dendrites, and axons; for SH-
SY5Y cells it was measured in the neurites and soma. NIH ImageJ was utilized to quantify the 
area of mitochondria and total area used for the mitochondrial content calculation. 
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3.2.5 Mitochondrial Trafficking 
In the dendrites of cortical neurons, Cox8-GFP-labeled mitochondria were imaged every 20 
seconds for a total of 2 minutes on days 2 and 4 after transfection. Images were captured on an 
inverted epifluorescence microscope (Olympus IX71) using Microsuite Five imaging software 
(Olympus). The neurons were imaged in PBS on a 37oC warmed stage with a 40X dry objective. 
Using NIH ImageJ, the number of mitochondria moving anterograde, retrograde, or remained 
static was quantified as a percentage of the total mitochondria analyzed.  
3.2.6 Mitochondrial Polarization 
Cortical neurons were transfected at 7 DIV. Neurons were stained with 50nM 
tetramethylrhodamine methyl ester (TMRM) (Invitrogen, Carlsbad, CA, USA) and imaged in 
Krebs-Ringer buffer with 12.5nM TMRM on day 3 after transfection. Staining intensity was 
measured in the cytosol and mitochondria using ImageJ. Mitochondrial membrane potential (Ψm) 
was calculated as the ratio of mitochondrial to cytosolic TMRM staining intensity as previously 
described. 
 
3.2.7 Calcium Imaging 
Cortical neurons were incubated with 5µM Fura2-AM (Invitrogen, Carlsbad, CA, USA) in 
normal buffer: 10mM HEPES pH 7.6, 140mM NaCl, 5mM KCl, 1mM CaCl2, 1mM MgCl2, and 
10mM glucose at 37oC for 1hr. Cells were washed in normal buffer for 10min, and then imaged 
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at 25oC. 50mM KCl in normal buffer was added to determine peak amplitude of calcium influx. 
To study calcium clearance, intracellular calcium was allowed to equilibrate in the presence of 
50mM KCl in normal buffer; Fura2-AM intensity was then measured upon washout with normal 
buffer. The curve between the Fura2-AM staining at equilibrium with 50mM KCl and at baseline 
after KCl washout was fit by a mono-exponential equation, which was used to calculate the time 
constant (t). 
3.3 BIOCHEMICAL ANALYSES 
3.3.1 Immunoblotting 
The cells were collected by scraping in scraping buffer: 25mM HEPES pH 7.5 (Research 
Organics, Inc., Cleveland, OH, USA), 50mM NaCl (Fisher Scientific, Pittsburgh, PA, USA), 
5mM EDTA (Fisher Scientific, Pittsburgh, PA, USA), 2mM PMSF (Acros Organics, Geel, 
Belgium), and 1mM sodium orthovanadate (Sigma-Aldrich Corp., St. Louis, MO, USA). All 
cells were lysed in lysis buffer: 25mM HEPES pH 7.5, 150mM NaCl, 5mM EDTA, 10% 
glycerol (Acros Organics, Geel, Belgium), 1.0% Triton X-100, 2mM, 1mM sodium 
orthovanadate, 2mM sodium pyrophosphate, and 0.1mM E-64. After incubating cells in lysis 
buffer for 30 minutes on ice, lysates were centrifuged at 15,000 x g for 15 minutes. The 
supernatant was removed, and the Bradford Assay with Coomassie Plus (Thermo Scientific, 
Rockford, IL, USA) was used to quantify the protein concentration. 25µg of total protein was 
separated by SDS-PAGE and transferred to a PDVF membrane. After blocking the blots with 5% 
milk in PBS with 0.3% Tween 20 (PBST) (Fisher Scientific, Pittsburgh, PA, USA) for one hour 
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at room temperature, primary antibodies were added at the indicated dilutions (Table 2), and the 
blots were incubated overnight at 4oC. The blots were then washed with PBST three times and 
incubated with horseradish peroxidase-conjugate secondary antibodies (1:5000) (GE Healthcare, 
Piscataway, NJ, USA) for one hour at room temperature. The blots were washed three times with  
PBST and developed using SuperSignal West Pico (Thermo Scientific, Rockford, IL, USA) or  
ECL plus (GE Healthcare, Piscataway, NJ, USA).  
 
 
Table 2: Antibodies and Dilutions for Immunoblotting 
 
3.3.2 Immunoprecipitation 
For hemagluttinin (HA)-tagged proteins, HEK 293 cells were lysed in PBS with 1.0% Triton X-
100 and incubated with 1µg of anti-HA antibody (Covance, Emeryville, CA, USA) and protein 
A agarose beads (Invitrogen, Carlsbad, CA, USA) overnight at 4oC. The beads were collected by 
centrifugation at 500 x g for 5 minutes. The beads were washed and centrifuged 5 times, and 
Antigen Dilution Company 
ADT2 1:500 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
Atg3 2µg/ml Sigma-Aldrich Corp., St. Louis, MO, USA 
Atg7 1:1000 Rockland Inc., Gilbersville, PA, USA 
β-Actin 1:5000 Sigma-Aldrich Corp., St. Louis, MO, USA 
GAPDH 1:8000 Abcam, Cambridge, MA, USA 
GFP 1:5000 Invitrogen, Carlsbad, CA, USA 
Lamin A/C 1:1000 Cell Signaling Technology, Danvers, MA, USA 
LC3 1:500 Nanotools, Teningen, Germany 
LC3 C-terminus 1:500 Abgent Inc., San Diego, CA, USA 
Phospho-LC3 S12 1:500 Abgent Inc., San Diego, CA, USA 
p62 1:100 BD Biosciences, San Diego, CA, USA 
VDAC 1:500 Merck KGaA, Darmstadt, Germany 
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then the bound proteins were eluted with 2X SDS-PAGE sample buffer: 33mM Tris-HCl pH 6.8 
(Fisher Scientific, Pittsburgh, PA, USA), 13.1% glycerol, 1% SDS (Bio-Rad, Hercules, CA, 
USA), 0.005% bromophenol blue (Fisher Scientific, Pittsburgh, PA, USA), and 25mM DTT 
(Sigma-Aldrich Corp., St. Louis, MO, USA). 
For GFP-tagged proteins, HEK 293 or SH-SY5Y cells were lysed and processed 
according to the manufacturer’s protocol for the µMACS Epitope Tag Protein Isolation Kit 
(Miltenyi Biotec, Auburn, CA, USA). Briefly, cells were lysed in µMACS lysis buffer on ice for 
30 minutes. The samples were centrifuged at 10,000 x g for 10 minutes, and the supernatant 
transferred to a tube containing 50µl of anti-GFP MicroBeads. The samples were incubated for 
30 minutes on ice prior to applying the samples to the µ Column on the µMACS Separator. The 
µ columns were washed with 900µl of µMACS lysis buffer. The bound proteins were eluted 
with hot µMACS elution buffer with 25mM DTT. 
3.3.3 Two-Dimensional Gel Electrophoresis 
The cells were lysed in lysis buffer as described above for immunoblotting. Proteins were 
acetone precipitated by adding 4 times the lysate volume of acetone (Sigma-Aldrich Corp., St. 
Louis, MO, USA) and incubating the mixture at -20oC for 1-2 hours. The precipitate was 
collected by centrifugation at 15,000 x g for 15 minutes. The supernatant was removed and the 
pellet was allowed to dry at room temperature for 20 min. The pellet was then resuspended in 
rehydration buffer: 7M urea (Invitrogen, Carlsbad, CA, USA), 2M thiourea (Invitrogen, 
Carlsbad, CA, USA), CHAPS (Sigma-Aldrich Corp., St. Louis, MO, USA), and 25mM DTT. 
50µg of protein with 4µl of pH 3-10 ampholytes (GE Healthcare, Piscataway, NJ, USA) in a 
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total volume of 125µl was then added to pH 3-10 IPG strips (GE Healthcare, Piscataway, NJ, 
USA).  
The IPG strips underwent rehydration and isoelectric focusing (IEF) using a PROTEAN 
IEF cell (Bio-Rad, Hercules, CA, USA). After IEF, the IPG strips were reduced with 
Equilibration Buffer I (Bio-Rad, Hercules, CA, USA) and alkylated with Equilibration Buffer II 
(Bio-Rad, Hercules, CA, USA), and then loaded onto an SDS-PAGE gel as the second 
dimension. The proteins were transferred and blotted as described above. 
3.3.4 Purification of Recombinant Proteins 
To obtain purified LC3, recombinant GST-LC3 (gift of Drs. Masahiro Shibata and Yasuo 
Uchiyama, Osaka University) was induced using IPTG in DH5α bacteria and purified on an 
immobilized glutathione column (Thermo Scientific, Rockford, IL, USA) according to the 
manufacturer’s specifications. To elute LC3 from the column, it was cleaved from the GST using 
Precision Protease (GE Healthcare, Piscataway, NJ, USA). 
3.3.5 In Vitro Kinase Assay  
For analysis of the PKA phosphorylation site on LC3, recombinant LC3 was incubated with 
recombinant PKA catalytic subunit (New England Biolabs Inc., Ipswich, MA, USA) for 2 hours 
at 30°C in 50mM Tris-HCl, 10mM MgCl2 with 200µM ATP. To detect phosphorylation by 
autoradiography, the kinase reaction was supplemented with 300µCi/µmol ATPγ32P. 
 25 
3.3.6 Metabolic Labeling to Determine Phosphorylation in Cultured Cells 
For detection of LC3 phosphorylation in cells, 293T cells were transfected with HA-LC3 
followed by treatment with DMSO, 10µM forskolin, or 10µM forskolin and 10µM H89 in the 
presence of 1mCi/ml 32P as H332PO4. All treatments were in the presence of 10µM rolipram, and 
for the final hour of incubation, 250nM okadaic acid and 10nM FK506. Cells were lysed in PBS 
with 1% Triton and proteins were immunoprecipitated and separated by SDS-PAGE as 
described above. Gels were silver stained and HA-LC3 bands were excised. 32P incorporation was 
measured as counts/minute (Beckman LS3801) and normalized to band intensity. 
3.3.7 Mass Spectrometry for Phosphosite and Protein Identification 
For the identification of phosphorylation sites on LC3, gel bands were excised and destained in 
100mM NH4(HCO3). The proteins were reduced with 2.5mM tris(2-carboxyethyl)phosphine 
(Sigma-Aldrich Corp., St. Louis, MO, USA) for 15 minutes at 65oC and alkylated with 3.75mM 
iodoacetamide (Sigma-Aldrich Corp., St. Louis, MO, USA) for 20 minutes at room temperature 
in the dark. Gel plugs were digested overnight with 8ng/µl chymotrypsin (Roche Diagnostics 
Corporation, Indianapolis, IN, USA) at room temperature. Peptides were extracted with 1:2 
(vol/vol) 5% formic acid/acetonitrile. Samples were desalted using a C18 ZipTip (Millipore, 
Billerica, MA, USA) and spotted for mass spectrometric analysis on a 4800 MALDI-TOF/TOF 
Analyzer (AB SCIEX, Foster City, CA, USA). Peptide phosphorylation was detected as a gain of 
80Da by MALDI-TOF-MS. Amino acid sequences were identified by subjecting peptides to 
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collision-induced dissociation during MS/MS. The loss of phosphoric acid (98Da) was indicative 
of phosphorylation during MS/MS. 
For the identification of LC3 or PINK1 interacting proteins, GFP-tagged LC3 or PINK1 
were immunoprecipitated as described above. Proteins were separated by SDS-PAGE and 
excised bands were processed for mass spectrometry. Proteins were identified in the SwissProt 
57.13 database limited to Metazoan organisms using the Mascot algorithm on Matrix Science  
(Mascot Server 2.3) with the search parameters listed in table 3. The requirements for protein 
identification included: presence of 2 or more unique peptides and a Mascot score greater than 62 
(p<0.05). 
 
Table 3: Mascot Search Parameters for Protein Identification 
 
Type of Search : MS/MS Ion Search 
Enzyme : Chymotrypsin 
Fixed Modification : Carbamidomethyl (C) 
Variable Modification : Oxidation (M) 
Mass Values : Monoisotopic 
Protein Mass : Unrestricted 
Peptide Mass Tolerance : ±50ppm 
Fragment Mass Tolerance : ±0.5Da 
Max Missed Cleavages : 2 




3.3.8 Microtubule Isolation 
Cortical neurons were washed with PBS, then lysed in cytoskeleton stabilization buffer: 10mM 
PIPES pH 6.8, 50mM KCl, 2mM EGTA, 1mM MgCl2, 2M glycerol, and 0.5% Triton X-100 for 
15 minutes at room temperature. The lysate was removed and centrifuged at 16,000 x g to collect 
polymerized tubulin in the pellet. The supernatant containing free tubulin was removed and 
labeled as the cytoplasmic fraction. Cytoskeleton stabilization buffer containing 0.5% SDS was 
added to the plate of neurons to collect polymerized tubulin. This was then added to the previous 
pellet containing polymerized tubulin and was labeled as microtubule fraction. The fractions 
were then immunoblotted as described above. 
 
3.4 STATISTICAL ANALYSIS 
The student’s t test was used to compare means between two groups. For comparisons between 
more than two groups, data was analyzed by one-way ANOVA with a Bonferroni correction for 
multiple comparisons. A p-value less than 0.05 was considered significant. 
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4.0  RESULTS 
4.1 LRRK2 NEURONAL DEGENERATION: A CELL CULTURE MODEL 
4.1.1 Mutant LRRK2 causes a depletion of dendritic mitochondria 
Since mitochondrial dysfunction has been implicated in PD, mitochondrial homeostasis was 
assessed by measuring the mitochondrial content levels in the soma, dendrites, and axons of 
cortical neurons using a mitochondrial marker, Cox8-GFP (Fig. 1A). Mutant LRRK2, but not 
wild type, significantly reduced the mitochondrial content in dendrites at 5 days after transfection 
(Fig. 1B), but not in the axons (Fig. 1E). This reduction in mitochondrial content was not due to 
a reduction in dendrites, since the dendritic area was similar in all groups (Fig. 1C). Interestingly, 
only the G2019S mutation affected the somatic mitochondrial content (Fig. 1D). Mutant LRRK2 
expression also caused a reduction in neuritic mitochondrial content in SH-SY5Y cells using 




Figure 1: Mutant LRRK2 depletes dendritic mitochondria.  
(A) Representative images of cortical neurons expressing vector or LRRK2 with Cox8-GFP. Dendrites were 
identified by MAP2 staining. Scale bar=50µm. Inset: 2X zoom of proximal dendrites showing a decrease in 
mitochondrial content in mutant LRRK2 groups. M=Mitochondria (green channel) and D=Dendrite (red channel). 
Scale bar=50µm. (B) Quantification of mitochondrial content (mitochondrial pixels/dendrite pixels) in dendrites 
(mean±SEM; n=19-32 neurons/group compiled from 3 independent experiments). *p<0.05 vs. vector (C) 
Quantification of dendrite area (mean±SEM; n=19-32 neurons/group compiled from 3 independent experiments). 
(D-E) Quantification of mitochondrial content in the soma and axons (mean±SEM; n=14-32 neurons/group 
compiled from 3 independent experiments). *p<0.05 vs. vector; ns=not significant vs. vector. 
 
4.1.2 Mutant LRRK2 does not cause defects in mitochondrial trafficking 
Dendritic mitochondrial content is controlled by biogenesis, degradation, and trafficking84. To 
determine if mutant LRRK2 disrupted mitochondrial trafficking, mitochondrial movement was 
measured in dendrites of cortical neurons. Mitochondrial that had a net movement away from the 
soma were classified as anterograde, and those that moved toward the soma were retrograde. If a 
mitochondrion did not move during the 2-minute imaging period, it was labeled as stationary. 
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There were no differences in mitochondrial trafficking between LRRK2 mutants and vector 
control (Fig. 2A-C). 
 
Figure 2: Mutant LRRK2 does not perturb mitochondrial traffic. 
(A-C) Mitochondrial movement was tracked using Cox8-GFP in the proximal dendrites of cortical neurons over a 2 
minute time period (mean±SEM; n=6-17 neurons/group compiled from 3 independent experiments). Mitochondrial 
movement was quantified as retrograde (movement towards the soma), anterograde (movement away from the 
soma), or stationary (no net movement).  
 
4.1.3 Mutant LRRK2 induces depolarization and autophagic degradation of 
mitochondria 
The effects of mutant LRRK2 on mitochondrial degradation, which is primarily executed by the 
autophagy pathway, was investigated next. Using the autophagosome marker, GFP-LC3, mutant 
LRRK2 elicited an increase in autophagosomes in neurons (Fig. 3A). Inhibition of autophagic 
degradation with bafilomycin A (Baf A) for 48 hours prevented the decreased in mitochondrial 
content caused by mutant LRRK2 (Fig. 3B). The effects of Baf A on autophagy were verified by 
immunoblotting for LC3. A decrease in autophagic degradation leads to an increase in 
autophagosomes and the LC3-II bound to autophagosomes (Fig. 3C). Autophagy induction was 
also inhibited autophagy induction using RNAi against the essential autophagy protein, Atg7. 
Similar to Baf A, RNAi against Atg7 prevented the reduction in mitochondrial content induced 
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by mutant LRRK2 (Fig. 3D). The efficiency of Atg7 knockdown and verification of autophagy 
inhibition was measured by immunoblotting (Fig. 3E). Decreased LC3-II levels are indicative of 




Figure 3: Mutant LRRK2 induces mitochondria degradation via autophagy. 
(A) Steady state autophagy levels were measured by counting the number of GFP-LC3 labeled autophagosomes 
(mean±SEM; n=20-30 neurons/group compiled from 3 independent experiments). *p<0.05 vs. vector. (B) 
Mitochondrial content was quantified in proximal dendrites in the presence and absence of bafilomycin A, an 
inhibitor of lysosomal fusion (mean±SEM; n=5-32 neurons/group compiled from 3 independent experiments). 
*p<0.05 vs. vector.  (C) Verification that bafilomycin A (Baf A) inhibits autophagic degradation. Inhibition of 
degradation is indicated by the increase in LC3-II. (D) Mitochondrial content was measured in the neurites of SH-
SY5Y cells in the presence or absence of RNAi against Atg7 (mean±SEM; n=26-58 cells/group compiled from 3 
independent experiments).. *p<0.05 vs. vector.  (E) Verification of RNAi-mediated reduction in Atg7; reduction in 




Mitochondrial depolarization has been identified as a signal to induce mitophagy85. To 
determine if mutant LRRK2 affected mitochondrial polarization, TMRM staining intensity was 
measured in the dendrites of neurons expressing mutant LRRK2. TMRM is a mitochondrial 
membrane potential-dependent dye, and mitochondrial polarization is directly proportional to the 
intensity of TMRM staining14. Mutant LRRK2, but not wild type, caused mitochondrial 
depolarization 3 days after transfection (Fig. 4A-B). The reduction in membrane potential 
precedes mitochondrial degradation since there is no difference in the area of proximal dendrite 




Figure 4: Mutant LRRK2 elicits mitochondrial depolarization. 
(A) Representative images of proximal dendrites stained with TMRM. Scale bar=20µm. (B) Quantification of 
mitochondrial membrane potential (Ym) as mitochondrial TMRM intensity divided by cytosolic TMRM intensity 
(mean±SEM; n=16-29 neurons/group compiled from 3 independent experiments).. *p<0.05 vs. vector. (C) 
Quantification of area occupied by mitochondria divided by dendrite area (mean±SEM; n=16-29 neurons/group 
compiled from 3 independent experiments). 
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4.1.4 Depletion of mitochondria precedes dendrite retraction 
As a measure of neuronal degeneration, total dendrite length was measured in neurons 
expressing mutant LRRK2. Mutant LRRK2, but not wild type, induced a reduction in dendrite 
length between 7-14 days after transfection (Fig. 5A-B). The dendrite degeneration is therefore 
downstream of mitochondrial depolarization and mitophagy elicited by mutant LRRK2. 
Moreover, inhibition of autophagy in SH-SY5Y cells, which prevents mitochondrial degradation, 
attenuated the neurite shortening elicited by mutant LRRK2 and MPP+, a neurotoxin model of 




Figure 5: Mutant LRRK2 induces autophagy-mediated neurite shortening. 
(A) Representative images of neurons expressing GFP and vector or LRRK2. Scale bar=100µm. (B) Quantification 
of dendrite length in cortical neurons (mean±SEM; n=10-35 neurons/group compiled from 3 independent 
experiments). *p<0.05 vs. vector. (C) Quantification of neurite length in SH-SY5Y cells expressing mutant LRRK2 
or treated with MPP+ for 24hrs (mean±SEM; n=50-100 cells/group compiled from 3 independent experiments). 
*p<0.05 vs. Empty vector siControl. 
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4.2 PINK1 PROTECTS AGAINST LRRK2-MEDIATED DEGENERATION 
4.2.1 PINK1 prevents autophagy, mitochondrial degradation, and neurite retraction 
caused by mutant LRRK2 
Since mutant LRRK2 disrupts mitochondrial homeostasis, the effects of PINK1, which maintains 
mitochondrial homeostasis and provides protection against toxin insults, on mutant LRRK2 were 
assessed. Overexpression of wild type PINK1, but not the PD-associated L489P mutant, 
prevented neurite shortening in SH-SY5Y cells caused by LRRK2 G2019S (Fig. 6A). Stable 
expression of wild type PINK1 in SH-SY5Y cells also prevented the autophagy induction and 
neuritic mitophagy elicited by LRRK2 G2019S (Fig. 6B). Furthermore, stable expression of wild 
type PINK1 prevented the autophagy induction and neuritic mitochondrial degradation (Fig. 6C-
D). Similar to cortical neurons, the mitochondrial degradation occurred primarily in the neurites, 





Figure 6: PINK1 prevents neurite retraction, autophagy induction and mitochondrial degradation elicited by 
mutant LRRK2. 
(A) Quantification of neurite lengths in SH-SY5Y cells expressing vector or LRRK2 G2019S and GFP or WT or 
L489P PINK1-GFP (mean±SEM; n=12-57 cells/group compiled from 2 independent experiments). *p<0.05 vs. 
corresponding vector group; ns=not significant. (B) Quantification of neurite lengths in SH-SY5Y cells stably 
expressing vector or PINK1 (mean±SEM; n=145-158 cells/group compiled from 3 independent experiments). 
*p<0.05 vs. vector transfected vector cell line. (C) Quantification of GFP-LC3 labeled autophagosomes in cells 
stably expressing vector or PINK1 (mean±SEM; n=92-116 cells/group compiled from 3 independent experiments). 
*p<0.05 vs. vector transfected vector cell line. (D-E) Quantification of neuritic or somatic mitochondrial content in 
cells stably expressing vector or PINK1 (mean±SEM; n=43-53 cells/group compiled from 3 independent 
experiments). *p<0.05 vs. vector transfected vector stable cell line; ns=not significant. 
4.2.2 PINK1 levels regulate the phosphorylation of Drp1 and LC3 
To determine the signaling mechanism(s) underlying PINK1-mediated neuroprotection, a 2-D 
gel electrophoresis approach was utilized to attempt to identify PINK1 substrates. The lysates 
from SH-SY5Y cells stably expressing an shRNA hairpin against PINK1 or a scrambled 
sequence were separated 2-D SDS-PAGE. The results indicated that a protein that regulates 
mitochondrial homeostasis, Drp1, and an essential autophagy protein, LC3, showed a spot 
pattern indicative of dephosphorylation in cells expressing PINK1 shRNA (Fig. 7A-B). In vitro 
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kinase assays were preformed to assess whether PINK1 directly phosphorylated either of these 
proteins; however, neither protein was a direct substrate for PINK1. 
 
 
Figure 7: PINK1 expression level alters the phosphorylation status of Drp1 and LC3. 
(A-B) 2-D immunoblots from SH-SY5Y cells stably expressing scrambled shRNA or PINK1 shRNA. Blots were 
probed for Drp1 or LC3. Increased phosphorylation status is correlated with increased staining intensity at lower 
pHs. Immunoblots represent 1 experiment. 
 
4.3 PKA PHOSPHORYLATES LC3 AND PREVENTS PARKINSONIAN 
NEURONAL DEGENERATION 
4.3.1 PKA suppresses autophagy induction and provides neuroprotection 
Since the phosphoregulation of Drp1 has been established, the phosphoregulation of LC3 was 
further investigated. Bioinformatic analysis identified consensus phosphorylation sites on LC3 
(Table 4). Since PKA provides protection against the neurotoxin, 6-hydroxydopamine, and 
suppresses autophagy induction in yeast and hepatocytes75, 81, 82, the effects of PKA on LC3 
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phosphorylation and autophagy regulation were measured. Therefore, the effects of PKA on 
autophagy were first assessed in neuronal cells. 
 
Table 4: Phosphorylation Site Prediction for LC3 
Site Kinase Score 
S3 Protein kinase C 0.66 
T6 Protein kinase C 0.86 
S12 Protein kinase C 0.50 
S12 Protein kinase A 0.61 
T93 p38MAPK 0.53 
T93 cdk5 0.53 
S96 Casein kinase II 0.54 
Y99 Insulin Receptor 0.51 
S101 Casein kinase II 0.62 
Y110 Insulin Receptor 0.52 
S115 DNA Protein kinase 0.62 
S115 ATM 0.57 
T118 Casein kinase I 0.52 
 
 
To determine if PKA activation regulates autophagy in neuronal cells, SH-SY5Y cells 
expressing GFP-RFP-LC3 were treated with rapamycin in the presence or absence of cAMP. The 
GFP-RFP-LC3 construct allows for analysis of autophagic flux, i.e., distinguishing between the 
inhibition of autophagy induction and the increase in autophagosome maturation, as both 
processes could lead to a decrease in the number of GFP-LC3 labeled autophagosomes. Early 
autophagosomes are GFP-RFP dual fluorescent puncta, which appear yellow, but late 
autophagosome are RFP only, since the acidic environment of the lysosome quenches the GFP 
fluorescence. Treatment with cAMP reduced the number of early autophagosomes after 1 hour of 
treatment with rapamycin; however, neither rapamycin nor cAMP had an effect on late 
autophagosomes at this time (Fig. 8A-B). cAMP also reduced the numbers of early and late 
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autophagosomes after 3 hours of rapamycin (Fig. 8C). These results indicate that cAMP 




Figure 8: cAMP suppresses autophagy induction. 
(A) Representative images of SH-SY5Y cells expressing RFP-GFP-LC3 treated with rapamycin and/or cAMP for 
1hr. Scale bar=20µm. (B-C) Quantification of early (yellow puncta) and late (red puncta) autophagosomes after 1 or 
3 hr of rapamycin and/or cAMP treatment (mean±SEM; n=50-55 cells/group compiled from 3 independent 
experiments). *p<0.05 vs. DMSO vehicle group, **p<0.05 vs. rapamycin vehicle group, and ns=not significant. 
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Treatment with cAMP also suppressed autophagy induced by MPP+ and the LRRK2-
G2019S mutation, two models of PD (9A-C). Furthermore, cAMP prevented neurite shortening 
in both models (Fig. 9D-E), indicating that autophagy inhibition by PKA activation provides 
neuroprotection. Utilizing subcellularly targeted of PKA the effects of nuclear and cytoplasmic 
PKA on autophagy suppression and neuroprotection were assessed. Untargeted PKA and 
cytoplasmic-targeted PKA (PKA-NES) equally suppressed autophagy induction elicited by 
rapamycin or LRRK2-G2019S, but nuclear-targeted PKA (PKA-NLS) failed to suppress 
autophagy induction (Fig. 10A-B). Similarly, only the untargeted PKA and cytoplasmic-targeted 
PKA prevented neurite shortening (Fig. 10C). These results suggest that PKA phosphorylates a 
cytoplasmic protein to suppress autophagy, which supports the hypothesis that PKA may 





Figure 9: cAMP suppresses autophagy and prevents neurite shortening. 
(A) Representative images of neurites from SH-SY5Y cells expressing GFP-LC3 and vector or LRRK2 G2019S in 
the presence or absence of cAMP. Bright GFP-LC3 puncta (>1.5 standard deviations above mean cytoplasmic 
fluorescence) were considered autophagosomes. Scale bar=20µm. (B-C) Quantification of GFP-LC3 labeled 
autophagosomes in SH-SY5Y cells expressing vector or LRRK2 G2019S (mean±SEM; n=80-90 cells/group 
compiled from 3 independent experiments) or treated with or without MPP+ (mean±SEM; n=50-55 cells/condition 
compiled from 3 independent experiments) in the presence and absence of cAMP. *p<0.05 vs. vehicle vector or 
control; **p<0.05 vs. vehicle LRRK2 G2019S or MPP+. (D-E) Quantification of neurite lengths in SH-SY5Y cells 
expressing vector or LRRK2 G2019S (mean±SEM; n=80-90 cells/condition compiled from 3 independent 
experiments) or treated with or without MPP+ (mean±SEM; n=50-60 cells/condition compiled from 3 independent 
experiments) in the presence or absence of cAMP. *p<0.05 vs. vehicle vector or control; **p<0.05 vs. vehicle 





Figure 10: Cytoplasmic PKA suppresses autophagy and prevents neuronal injury. 
(A) Quantification of endogenous LC3-labeld autophagosomes in SH-SY5Y cells in the presence and absence of 
rapamycin (mean±SEM; n=35-45 cells/group compiled from 3 independent experiments). *p<0.05 vs. GFP vehicle 
group; **p<0.05 vs. GFP rapamycin group. (B) Quantification of endogenous LC3-labeled autophagosomes in SH-
SY5Y cells expressing vector or LRRK2 G2019S (mean±SEM; n=80-90 cells/group compiled from 3 independent 
experiments). *p<0.05 vs. GFP vector group; **p<0.05 vs. GFP LRRK2 G2019S group. (C) Quantification of 
neurite lengths in SH-SY5Y cells expressing vector or LRRK2 G2019S (mean±SEM; n=90-130 cells/group 
compiled from 3 independent experiments). *p<0.05 vs. GFP vector group; **p<0.05 vs. GFP LRRK2 G2019S 
group. PKA-NLS=nuclear-targeted PKA; PKA-NES=cytoplasmic-targeted PKA. 
 
4.3.2 Identification of the PKA phosphorylation site on LC3 
To determine if PKA phosphorylates LC3, 2-D immunoblotting as performed on neurons in the 
presence or absence of forskolin, an activator of adenylyl cyclase, which produces cAMP and 
stimulates PKA. Forskolin treatment increased the staining intensity of the more acidic spot, 
indicative of increased phosphorylation (Fig. 11A). HEK293 cells expressing HA-LC3 were then 
rabiolabeled in the presence of forskolin or forskolin and the PKA inhibitor, H89. HA-LC3 was 
then immunoprecipitated and the incorporation of 32P was measured. Forskolin increased the 
incorporation of 32P into LC3, which was reduced by H89 (Fig. 11B), indicating that PKA 
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increases the phosphorylation of LC3 in cultured cells. Finally an in vitro kinase assay was used 
to determine if PKA directly phosphorylated LC3. Recombinant PKA and LC3 were incubated 
together with ATP-γ32P and then separated by SDS-PAGE. Indeed, incubation with PKA 
increased the phosphorylation of LC3 as detected by autoradiogram (Fig. 11C), verifying that 
LC3 is a direct substrate of PKA. 
 
 
Figure 11: PKA phosphorylates LC3. 
(A) 2-D immunoblot from cortical neurons treated with or without forskolin for 1hr. Blots were probed for LC3, and 
increased phosphorylation status is indicated by an increased staining intensity of the more acidic spots. 
Immunoblots represent 1 experiment. (B) Immunoprecipitation of HA-LC3 from cells treated with vehicle, 
forskolin, or forskolin and H89 for 5hrs in the presence of 32P-inorganic phosphate. Bands were excised from the 
gel, and radioactivity incorporation was quantified using a scintillation counter. Image is representative of 3 
independent experiments; graphical data is mean±SEM with 1 lane/group compiled from 3 independent 
experiments. *p<0.05 vs. vehicle; **p<0.05 vs. forskolin. (C) In vitro kinase assay with recombinant PKA and LC3 




To determine the function of LC3 phosphorylation, the PKA phosphorylation site was 
identified by mass spectrometry. Cold in vitro kinase assays were subjected to MALDI-TOF-
MS, and phosphopeptides were identified by the indicative 80Da shift due to the addition of 
phosphate. Incubation with PKA produced a peak at m/z 901.41 that was not present in LC3 
alone (Fig. 12A-B). This appearance of the peak at m/z 901.41 was accompanied by the loss of 
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the peak at m/z 821.33 (Fig. 12A-B). Analysis by MS/MS identified the peaks at m/z 821.33 and 
901.41 as the amino acid sequence KQRRSF spanning the LC3 residues 8-13. The shift of 80Da 
is indicative of a phosphorylation; this was confirmed by MS/MS analysis, which showed the 
loss of the phosphate from S12 when the m/z 901.41 peak was subjected to collision-induced 
dissociation (Fig. 12C). Together these data suggest that PKA phosphorylates LC3 at the S12 
residue. To verify that this is the only PKA site, an in vitro kinase assay was performed with an 
S12A mutant. Deletion of this phosphorylation site abolished PKA phosphorylation of LC3 (Fig. 
12D). Furthermore, using an antibody developed against the PKA phosphorylation site on LC3, 
the forskolin-induced phosphorylation of endogenous LC3 was detected in neurons (Fig. 12E).  
 
 
Figure 12: Identification of PKA phosphorylation site on LC3. 
(A-B) Representative mass spectra from in vitro kinase assay with recombinant PKA and LC3. Spectra are 
representative of 3 independent experiments. A shift from m/z 821.33 to 901.41 was observed in the presence of 
PKA. (C) Representative spectrum from tandem mass spectrometry analysis of the peak at m/z 901.41. The 
spectrum is representative of 3 independent experiments. Loss of phosphate peak is indicated as MH-H3PO4, and 
ions used for sequence analysis are labeled in the inset. (D) In vitro kinase assay with recombinant PKA and LC3-
WT or -S12A in the presence of ATPγ32P. Radioactivity was measured by autoradiography, which represents 1 
experiment. (E) Immunoblot from cortical neurons treated with or without forskolin for 1hr. Phospho-LC3 was 
detected with a custom antibody against the phosphorylated S12 residue. Immunoblots represent 1 experiment. 
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4.3.3 LC3 dephosphorylation is necessary for autophagy induction 
To determine whether phosphorylation status is affected by autophagy induction, SH-SY5Y cells 
were treated with either rapamycin or MPP+ to induce autophagy. The induction of autophagy 
by either treatment decreased the phosphorylation of LC3 at the S12 residue (Fig. 13A-B). 
Cotreatment with cAMP prevented this decrease in phosphorylation (Fig. 13B). To determine if 
LC3 dephosphorylation was sufficient to induce autophagy, the GFP-LC3-S12A mutant was 
expressed in SH-SY5Y cells and the amount of LC3-II or the number of GFP-LC3 puncta was 
measured. The S12A phospho-null mutant formed more LC3-II and more LC3 puncta, regardless 
of the cellular compartment (Fig. 13 C-D). These data suggest that the dephosphorylation of LC3 





Figure 13: LC3 is dephosphorylated during autophagy induction. 
(A) Immunoblot from SH-SY5Y cells treated with or without rapamycin for 1hr. Blot was probed for phospho-LC3 
and LC3 to determine if autophagy induction affected LC3 phosphorylation. Immunoblots are representative of 2 
independent experiments. (B) Immunoblot from SH-SY5Y cells treated with or without MPP+ in the presence or 
absence of cAMP for 24hrs. Immunoblots represent 1 experiment. (C) Immunoblot from SH-SY5Y cells expressing 
GFP-LC3-WT or -S12A. Immunoblots represent 3 independent experiments. (D) Quantification of GFP-LC3-WT or 
-S12A labeled autophagosomes in SH-SY5Y cells and stratified by cellular compartment (mean±SEM; n=100-115 
cells/group compiled from 3 independent experiments). *p<0.05 vs. WT neurite, *p<0.05 vs. WT soma, and 
***p<0.05 vs. WT total. 
 
4.3.4 PKA phosphorylation of LC3 suppresses autophagy and prevents neuronal 
degeneration 
To determine if dephosphorylation of LC3 was necessary for autophagy induction, SH-SY5Y 
cells expressing the phosphomimetic, GFP-LC3-S12D, were treated with rapamycin. Similar to 
PKA activation, the S12D mutant formed fewer puncta in the presence of rapamycin (Fig. 14A-
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B). Furthermore, in the presence of MPP+ or LRRK2-G2019S, the S12D mutant also formed 
fewer puncta (Fig. 14C-D), suggesting that PKA regulates pathologic and metabolic induction of 




Figure 14: LC3 phosphorylation suppresses autophagy. 
(A) Representative images from SH-SY5Y cells expressing GFP-LC3-WT or -S12D. Scale bar=20µm. (B) 
Quantification of GFP-LC3-WT or -S12D labeled autophagosomes in SH-SY5Y cells in the presence or absence of 
rapamycin (mean±SEM; n=70-80 cells/group compiled from 3 independent experiments). *p<0.05 vs. WT vehicle; 
**p<0.05 vs. WT rapamycin. (C) Quantification of GFP-LC3-WT or -S12D labeled autophagosomes in SH-SY5Y 
cells expressing vector or LRRK2 G2019S (mean±SEM; n=110-115 cells/group compiled from 3 independent 
experiments). *p<0.05 vs. WT vector; **p<0.05 vs. WT LRRK2 G2019S. (D) Quantification of GFP-LC3-WT or -
S12D labeled autophagosomes in SH-SY5Y cells treated with or without MPP+ (mean±SEM; n=85-95 cells/group 
compiled from 3 independent experiments). *p<0.05 vs. WT vehicle; **p<0.05 vs. WT MPP+. 
 
 
Since autophagy inhibition by PKA activation prevented neurite shortening, the 
phosphomimetic LC3 was analyzed to determine if it was sufficient to recapitulate the protective 
effects. Indeed, in SH-SY5Y cells, expression of the LC3-S12D mutant prevented neurite 
shortening when cells were treated with MPP+ or transfected with LRRK2-G2019S (Fig. 15A-
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B). Moreover, LC3-S12D suppressed the neurite shortening and branch simplification in neurons 
(Fig. 15C-D). 
 
Figure 15: LC3 phosphorylation reduces neurite shortening. 
(A-B) Quantification of neurite length in SH-SY5Y cells expressing GFP-LC3-WT or -S12D and vector or LRRK2 
G2019S or treated with or without MPP+ (mean±SEM; n=110-115 cells/group compiled from 3 independent 
experiments for A and n=85-95 cells/group compiled from 3 independent experiments for B). *p<0.05 vs. WT 
vector or vehicle; **p<0.05 vs. WT LRRK2 G2019S or MPP+. (C-D) Quantification of neurite length and branch 
points in cortical neurons expressing GFP-LC3-WT or -S12D and vector or LRRK2 G2019S mean±SEM; n=30-40 
neurons/group compiled from 3 independent experiments). *p<0.05 vs. WT vector; **p<0.05 vs. WT LRRK2 
G2019S. 
 
4.3.5 The role of phosphorylation on LC3 function 
To determine how phosphorylation affected LC3 function, LC3 interacting partners were 
identified using immunoprecipitations with either GFP-tagged or HA-tagged-LC3 WT, S12A, or 
S12D followed by mass spectrometry analysis. Although the abundance of most interacting 
proteins was not effected by phosphorylation status, the interactions between LC3 and CLH1, 
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AP2B1, HADHA, and HADHB showed a slight reduction in the S12D group as compared to the 
S12A group (Fig. 16A-B). These results indicate that phosphorylation of LC3 might regulate its 
interaction with endocytosis machinery (CLH1 and AP2B1) and beta-oxidation/fatty acid 
degradation in the mitochondria (HADHA and HADHB). 
In addition to these differential interactions, many new LC3 interactions were identified 
(Fig. 16A-B; Table 5). In addition to its roles in microtubule stability and autophagy, these new 
interactions suggest that LC3 could play a role in membrane trafficking other than autophagy, 
such as endocytosis or vesicle trafficking (CLH1 and AP2B1), RNA processing, mRNA splicing, 
and transcriptional regulation (SAFB1, DHX9, PUF60, RBMX, TRA2B, ROA2, THOC4, 
SFRS9, and SFRS3), fatty acid beta-oxidation (HADHA and HADHB), or even response to 
DNA damage (PARP1). PUF60 was also found to interact with GFP (data not shown), 




Figure 16: Identification of new LC3 interacting proteins. 
(A) GFP-LC3-WT, -S12A, and -S12D was immunoprecipitated from HEK293 cells. Interacting proteins were 
separated by SDS-PAGE and identified by MALDI-TOF-TOF mass spectrometry using the parameters listed in 
table 3. HNRNPA2B1was identified comigrating with GFP-LC3 and is not indicated on the gel. All proteins listed 
had Mascot scores >62 (p<0.05) and at least 2 unique peptides. (B) HA-LC3-WT, -S12A, and -S12D was 
immunoprecipitated from HEK293 cells and proteins were analyzed as in (A). All proteins listed, except HADHB, 
had Mascot scores >62 (p<0.05) and at least 2 unique peptides; HADHB had only 1 unique peptide identified. 














Table 5: LC3 Interacting Proteins 
Gene Protein Function 
AP2B1 Adapter-related protein complex 2  beta 1 Endocytosis/vesicle traffic 
CLH1 Clathrin heavy chain 1 Endocytosis/vesicle traffic 
SAFB1 Scaffold attachment factor B RNA processing/transcription 
DHX9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 RNA processing/transcription 
RBMX RNA binding motif protein, X-linked RNA processing/transcription 
TRA2B Transformer 2 beta homolog RNA processing/transcription 
HNRNPA2B1 Heterogeneous nuclear ribonucleoprotein 
A2/B1 
RNA processing/transcription 
THOC4 THO complex 4 RNA processing/transcription 
SFRS9 Serine/arginine-rich splicing factor 9 RNA processing/transcription 
SFRS3 Serine/arginine-rich splicing factor 3 RNA processing/transcription 
PARP1 Poly (ADP-ribose) polymerase 1 DNA damage 
HADHA Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-
CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), alpha subunit 
Fatty acid beta-oxidation 
HADHB Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-
CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), beta subunit 
Fatty acid beta-oxidation 
 
 
Although mass spectrometry did not identify tubulin or microtubule-binding proteins as 
LC3 interactors, LC3 is a microtubule-associated protein86. Cortical neurons were treated with 
forskolin to increase LC3 phosphorylation or rapamycin to decrease LC3 phosphorylation to 
assess whether phosphorylation altered its ability to bind to microtubules. However, after 
separating free and polymerized tubulin, there were no discernable differences in LC3 levels 
between the treatments (Fig. 17), indicating the phosphorylation at S12 does not affect the 




Figure 17: LC3 phosphorylation does not alter microtubule binding of LC3. 
Cortical neurons were treated with DMSO, forskolin, or rapamycin for 1hr prior to microtubule isolation. Whole cell 
lysates, cytosplasmic fractions, and microtubule fractions were separated by SDS-PAGE and immunoblotted for 
LC3. Immunoblots represent 2 independent experiments. 
 
 
To determine if LC3 phosphorylation altered its interaction with other autophagy proteins 
not identified by mass spectrometry, immunoprecipitations followed by immunoblotting was 
used to analyze specific LC3 interactions. Phosphorylation does not affect the interactions 
between LC3 and Atg3 or Atg7 when autophagy is induced with rapamycin (Fig. 18A). 
However, the phosphomimetic LC3 showed a reduction in its interaction with p62 during 
autophagy induction with rapamycin (Fig. 18B). This reduction in LC3-p62 interaction could 
result in the reduced recruitment of phospho-LC3 to forming autophagosomes around cargo 
recognized by p62. Together these results suggest that PKA phosphorylation of LC3 may 





Figure 18: LC3 phosphorylation perturbs interaction with p62, but not with Atg7 or Atg3. 
(A-B) SH-SY5Y cells expressing GFP-LC3-S12A or -S12D were treated with rapamycin followed by 
immunoprecipitation of GFP-LC3. Immunoblots were probed for Atg3, Atg7, or p62. Immunoblots represent 1 
experiment. 
4.4 RESTORATION OF CALCIUM HOMEOSTASIS PREVENTS INJURY CAUSED 
BY MUTANT LRRK2 
4.4.1 Mutant LRRK2 causes an imbalance in calcium homeostasis 
In addition to its effects on mitochondrial homeostasis, mutant LRRK2 also causes an imbalance 
in calcium buffering (Fig. 19). There were no differences between depolarization-induced 
calcium influxes in vector- or mutant LRRK2-expressing neurons (Fig. 19A). However, mutant 
LRRK2-expressing neurons had a delay in calcium clearance after removing the depolarizing 
stimuli (Fig. 19B-C). To determine if calcium imbalance was upstream or downstream of the 
mutant LRRK2 elicited decrease in mitochondrial homeostasis, the mitochondrial membrane 
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potential and mitochondrial content was measured in the presence and absence of BAPTA-AM, 
an intracellular calcium chelator. BAPTA-AM treatment prevented the reduction in 
mitochondrial membrane potential, suppressed autophagy, and restored the mitochondrial 
content to control levels (Fig. 20A-C). Together these results indicate the mutant LRRK2 causes 
a deficit in calcium clearance that leads to a decrease in mitochondrial polarization and content 
in the dendrites.  
 
 
Figure 19: Mutant LRRK2 induces an imbalance in calcium homeostasis. 
(A) Quantification of calcium influx peak amplitude stimulated with KCl in cortical neurons loaded with Fura2-AM 
(mean±SEM; n=5-10 neurons/group compiled from at least 3 independent experiments). (B) Representative traces 
illustrating a delay in calcium clearance in neurons expressing mutant LRRK2. KCl was washed out at the 
arrowhead. Inset: Monoexponential fits for the calcium decay. (C) Quantification of time constant for calcium decay 
in neurons expressing vector or LRRK2 after removal of KCl (mean±SEM; n=5-9 neurons/group compiled from at 







Figure 20: Calcium chelation prevents mitochondrial depolarization, autophagy, and mitochondrial 
degradation. 
(A) Quantification of dendritic mitochondrial polarization in cortical neurons in the presence and absence of calcium 
chelation with BAPTA-AM (mean±SEM; n=15-24 neurons/group compiled from 3 independent experiments). 
*p<0.05 vs. vector. (B) Quantification of GFP-LC3 labeled autophagosomes in cortical neurons in the presence and 
absence of BAPTA-AM (mean±SEM; n=13-30 neurons/group compiled from 3 independent experiments). *p<0.05 
vs. vector. (C) Quantification of dendritic mitochondrial content in cortical neurons in the presence and absence of 
BAPTA-AM (mean±SEM; n=19-34 neurons/group compiled from 3 independent experiments). *p<0.05 vs. vector. 
 
4.4.2 Voltage-gated calcium channel inhibitors restore calcium homeostasis 
Since there are extracellular and intracellular sources of calcium that could be responsible for the 
elevation in intracellular calcium in neurons expressing mutant LRRK2, EGTA was used to 
determine which stores were important for the mitochondrial degradation elicited by mutant 
LRRK2. Similar to chelation of intracellular calcium with BAPTA-AM, EGTA, which is cell 
impermeable, prevented mitochondrial degradation in mutant LRRK2-expressing cells by 
chelating extracellular calcium (Fig. 21A). These results indicated that extracellular calcium 
plays a role in LRRK2-induced mitochondrial degradation. 
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Voltage-gated calcium channels conduct the majority of calcium influx in the dendrites8, 
so this study assessed whether inhibiting these channels would restore calcium homeostasis and 
abolish mitochondrial degradation caused by mutant LRRK2. Inhibition of the L-type calcium 
channels with nitrendipine prevented mitochondrial degradation in both the G2019S and R1441C 
LRRK2 groups; however, inhibition of the N-, P/Q-, and R-type calcium channels with a mixture 
of NiCl2, ω-agatoxin, and ω-conotoxin provided protection in only the R1441C group (Fig. 
21B). Finally, the effects of restoring calcium homeostasis on the neurite shortening elicited by 
mutant LRRK2 was assessed. Treatment with either BAPTA-AM or nitrendipine attenuated the 
dendrite shortening in neurons expressing mutant LRRK2 as compared to control (Fig. 21C-D). 
Similar to its effects on mitochondrial content, the mixture of NiCl2, ω-agatoxin, and ω-
conotoxin suppressed the dendrite shortening in the R1441C group, but not the G2019S group 
(Fig. 21D). Based on these results, restoration of calcium homeostasis prevents mitochondrial 




Figure 21: Calcium channel inhibitors prevent mitochondrial degradation and dendrite shortening. 
(A-B) Quantification of dendritic mitochondrial content in neurons in the presence and absence of EGTA, 
nitrendipine (Nit), or a mixture of NiCl2, ω-agatoxin, and ω-conotoxin (Mix) (mean±SEM; n=14-31 neurons/group 
compiled from 3 independent experiments). *p<0.05 vs. vector. (C-D) Quantification of dendrite length in neurons 
in the presence and absence of BAPTA-AM, nitrendipine, or a mixture of NiCl2, ω-agatoxin, and ω-conotoxin 
(mean±SEM; n=10-35 neurons/group compiled from 3 independent experiments). *p<0.05 vs. vector. 
4.5 ELUCIDATION OF A PINK1 SIGNALING NETWORK 
4.5.1 Identification of PINK1 interacting proteins 
As previously mentioned, overexpression of wild type PINK1 suppressed the autophagy, 
mitochondrial degradation, and neurite shortening induced by mutant LRRK2 expression (Fig. 
6A-D). While this could be due to phospho-regulation of LC3 or Drp1, neither of this proteins 
 57 
are direct substrates for PINK1 (Fig. 7A-B). To identify possible direct mechanisms underlying 
PINK1 neuroprotection, immunoprecipitations with PINK1-GFP were performed. These results 
confirmed that PINK1 interacts with Hsp70, Hsp90, and Cdc37 (Fig. 22A-B) as previously 
reported87, which validates this method. In addition to these known interacting proteins, ADT2 
was also identified as a PINK1 interacting protein (Fig. 22A-B). Interestingly, the engineered 
kinase-dead mutant K219M and the PD-associated L489P mutant PINK1 displayed increased 
binding to ADT2 as compared to WT PINK1 (Fig. 22C). 
To determine if PINK1 expression altered the phosphorylation status of ADT2, 2D-
immunoblotting was performed from HEK 293 cells expressing either GFP or PINK1-GFP. The 
phosphorylation status of ADT1 and 3 was similar in the cells expressing PINK1-GFP as 
compared to GFP (Fig. 23A; top and bottom spots). However, there was a shift towards 
decreased phosphorylation of ADT2 (Fig. 23A; middle set of spots) in the PINK1-GFP sample, 
suggesting that PINK1 may regulate the phosphorylation status of ADT2 through an indirect 
mechanism. Interestingly, VDAC, which interacts with ADT2, displayed an increased spot 
intensity of the more acidic spots and the appearance of a new highly acidic spot in the PINK1-
GFP sample, indicative of an increase in phosphorylation (Fig. 23B). This increased 
phosphorylation is visible in all VDAC isoforms (Fig. 23B; VDAC1: top set of spots, VDAC2: 
middle set of spots, and VDAC3: bottom set of spots).  These results indicate that PINK1 
interacts with proteins that comprise the mitochondrial permeability transition pore, suggesting 
that PINK1 may provide neuroprotection by regulating ion and metabolite flow as one 




Figure 22: Identification of new PINK1 interacting proteins. 
(A) PINK1-GFP was immunoprecipitated from HEK293 cells and interacting proteins were separated by SDS-
PAGE and identified by MALDI-TOF-TOF mass spectrometry using the parameters listed in table 3. All the listed 
proteins had Mascot scores >62 (p<0.05) and at least 2 unique peptides, with the exception of EF1A1, which had no 
peptides positively identified. Proteins that were identified in both PINK1 and GFP lanes are marked with an 
asterisk; (#) denotes previously identified interactions. Gel is representative of 2 independent experiments. Inset: 2X 
magnified region of gel highlighting the presence of the ADT2 band in the PINK1 WT and K219M lanes only. (B) 
Immunoblot for PINK1-GFP immunoprecipitated from HEK293 cells to validate the interaction between PINK1 and 
ADT2. Immunoblots represent 2 independent experiments. (C) Optical density (densitometry) of ADT2 bound to 
PINK1. Densitometry is the ADT2 density normalized to PINK1 density. Graphical data is mean±SEM with 1 










Figure 23: PINK1 levels regulate VDAC phosphorylation status. 
(A-B) 2-D immunoblots from HEK293 cells expressing GFP or PINK1-GFP. Blots were probed for ADT2/3 or 
VDAC. Increases in phosphorylation status are indicated as increased staining intensity of more highly acidic spots. 
Immunoblots represent 1 experiment. 
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5.0  DISCUSSION 
5.1 MITOCHONDRIAL DYSFUNCTION IN THE LRRK2 MODEL 
Mitochondrial dysfunction has been implicated in the pathogenesis of PD for over 20 years. With 
the discovery of mutations in mitochondrial-targeted proteins, the connection between 
mitochondrial dysfunction and PD has become even stronger. Interestingly, one of the most 
common familial PD mutations, the LRRK2 G2019S mutation, occurs in a protein minimally 
localized with the mitochondria. This study has shown that mutations in LRRK2 do indeed cause 
mitochondrial dysfunction (Fig. 4). The data suggest that LRRK2 mutants cause a deficit in 
calcium homeostasis that leads to mitochondrial stress and dysfunction, due to its attempts to 
buffer the excess intracellular calcium.  
Mitochondrial calcium buffering plays an important role in synaptic plasticity, 
dendrite/axon morphology, and cell survival8, 84. The capacity to buffer calcium relies on the 
electrochemical gradient established across the inner mitochondrial membrane11. The 
mitochondrial polarization derived from this gradient is essential to mitochondrial calcium 
uptake11. Upon calcium uptake, the electrochemical gradient is diminished, resulting in a slight 
depolarization11, similar to the observations with mutant LRRK2 expressing cells in this study 
(Fig. 4). Conversely, mitochondrial depolarization reduces the ability of mitochondria to buffer 
calcium, leading to elevated intracellular calcium, potentially leading to cell death8, 10, 11. This 
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study indicates that LRRK2 mutants cause an increase in intracellular calcium (Fig. 19), which 
then leads to mitochondrial depolarization as a compensatory mechanism to buffer the calcium, 
since calcium chelation prevents the mitochondrial depolarization elicited by mutant LRRK2 
(Fig. 20).  
In addition to its effects on calcium buffering, which affect mitochondrial homeostasis, 
LRRK2 also interacts with parkin88, an E3 ubquitin ligase that regulates mitochondrial 
degradation. Parkin increases depolarization-induced mitochondrial degradation by autophagy, 
suggesting that it functions to regulate mitochondrial quality control85. Although the effects of 
LRRK2 mutations on this interaction remain unknown, it is possible that mutations in LRRK2 
could perturb the parkin-mediated mitochondrial homeostasis. Interestingly, parkin expression 
protects against mutations in PINK1 and LRRK226, 28, 89, which places parkin downstream of 
PINK1, which is downstream of LRRK2 according to this study. A reduction in mitochondrial 
homeostasis could feedback to cause or exacerbate deficits in calcium buffering. 
Parkin also regulates synapse stability by enhancing the removal of glutamatergic 
synapses90. Glutamatergic transmission causes influxes of calcium through NMDA and voltage-
gated calcium channels during neuronal depolarization8. By regulating the number of 
glutamatergic synapses, parkin may help balance of inhibitory and excitatory inputs, and in 
doing so could reduce the effects of excitotoxicity due to excessive intracellular calcium. This 
reduction in calcium influx, either by inhibition of voltage-gated calcium channels in this study 
(Fig. 20 and 21) or by reducing excitatory synapses, could prevent mitochondrial stress and 
dysfunction in response to deficits in calcium clearance. This finding suggests that parkin may 
act through multiple mechanisms to prevent prolonged elevations in calcium and to restore 
mitochondrial homeostasis in our model as well as others. Furthermore, it is possible that 
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LRRK2 could regulate glutamatergic synapses through its interaction with parkin, and mutations 
in LRRK2 could disrupt this function. Overall, mutations in LRRK2 could cause mitochondrial 
dysfunction through parkin-mediated and parkin-independent mechanisms that disrupt calcium 
homeostasis preceding degeneration. 
Although this study suggests that mutant LRRK2 affects mitochondrial function through 
an indirect, calcium-mediated mechanism, we cannot rule out direct effects since 10% of LRRK2 
localizes to the mitochondria. Since many mitochondrial proteins exist as phosphoproteins and 
phosphorylation has been shown to regulate mitochondrial proteins such as enzymes in the 
electron transport chain and the permeability transition pore, it is possible that LRRK2 could 
directly phosphorylate mitochondrial proteins to alter mitochondrial function. A recent study has 
even shown that LRRK2 interacts with VDAC and ADT91. Direct interactions with these 
proteins could be an alternative mechanism underlying the mutant LRRK2 induced mitochondria 
depolarization, since VDAC and ADT regulate the formation of the mitochondrial permeability 
transition pore that plays a role in mitochondrial depolarization15. This could suggest a more 
direct relationship between PINK1 and LRRK2, whereby they could directly counteract the 
influence of the other by differentially modifying the same proteins, a theory that will be 
discussed later.  
LRRK2 localization to the mitochondria has been thus far restricted to association with 
the outer membrane92. This finding would place LRRK2 in a position where it could also affect 
mitochondrial dynamics, such as fusion or fission, which are regulated by proteins associated 
with the mitochondrial outer membrane and are required for mitophagy25. Although LRRK2 
mutants did not cause deficits in mitochondrial trafficking (Fig. 2), there was also no 
compensatory increase in mitochondrial delivery to the neurites, indicating that mutant LRRK2 
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may perturb compensatory mechanisms for protection such as upregulation of mitochondrial 
biogenesis.  Interestingly, we found that PINK1 might also regulate mitochondrial fusion and 
fission through the phosphoregulation of Drp1 (Fig. 7A). Without proper fusion/fission events, 
mitochondrial biogenesis declines and mitochondria cannot be delivered to neurites93. Altered 
mitochondrial dynamics coupled with an increase in mitochondrial degradation would explain 
the progressive shortening of neurites devoid of mitochondria reporterd in this study. The 
overexpression of PINK1 may provide compensation for mutations in LRRK2 by enhancing the 
delivery of mitochondria to dendrites, thus replacing those lost through mitophagy. Mutant 
LRRK2 could also perturb the compensatory delivery of mitochondria through its effects on 
microtubule dynamics42. Regardless of the mode of mitohcondrial injury (calcium-mediated, 
direct effects on mitochondrial function, or effects on mitochondrial dynamics), inhibition of 
autophagic degradation prevents the neurite shortening that follows mitochondria depletion (Fig. 
5). 
5.2 THE ROLE OF LC3 PHOSPHORYLATION 
LC3 was initially identified as a microtubule-associated protein that functions to regulate 
microtubule stability and dynamics86. Since microtubules provide support for axons and 
dendrites in addition to their function as intracellular highways, LC3 phosphorylation could 
directly play a role in neurite shortening. There were no defects in microtubule binding caused 
by either the phosphomimetic or phospho-null LC3 mutations (Fig. 17); however, effects of 
phosphorylation on LC3 binding to MAP1B, which also binds to LC3 and tubulin, were not 
assessed. Increased interaction with MAP1B has been reported to decrease autophagy levels and 
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therefore, could be one mechanism through which the phosphorylation of LC3 suppresses 
autophagy induction94. 
After its initial discovery, LC3 has become widely known as an essential autophagy 
protein. While its phosphorylation status does not perturb its interaction with Atg3 or Atg7 (Fig. 
18), which catalyze the ubiquitin-like reaction that conjugates LC3 to the lipid bilayer of the 
autophagosome, we did find that phosphorylated LC3 displays a reduced affinity or a delayed 
recruitment to p62 (Fig. 18). Cargo adaptors such as p62 or NBR1 allow for the recognition of 
aggregates and ubiquitinated proteins by autophagosomes, aiding in their selective degradation64, 
65. While autophagosome formation around cargo has only been observed in a few cases, 
specifically mitophagy95, it would not be surprising if autophagosomes formed around their 
cargo rather than phagophores trafficking to their cargo. This theory would allow for high 
specificity of cargo recognition since the cargo would determine the location and size of the 
forming autophagosome. As such, the desired cargo would be sequestered with minimal 
engulfment of non-targeted proteins/organelles. In this scenario, p62 or NBR1 would recruit LC3 
to form autophagosomes around their bound cargo, rather than phagophore-bound LC3 
recognizing cargo as it engulfs cytoplasmic components. The reduced interaction between 
phosphorylated LC3 and p62 suggests that this could be a regulatory mechanism for cargo 
selection that is modulated by PKA.  
Besides p62-mediated cargo selection, LC3 can interact directly with cargo since it lines 
the lumen of the autophagosome. The charge alteration on the N-terminus of LC3 that results 
from phosphorylation could alter its interactions with other negatively charged cargo, such as 
phospholipids that comprise the mitochondrion, endoplasmic reticulum, Golgi apparatus, and 
other membrane-bound organelles. While PKA phosphorylation of LC3 does not suppress basal 
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autophagy, it prevents stimulus-induced autophagy (Fig. 14). One way that this could happen is 
through altered targeting of substrates for degradation. By altering cargo recognition, PKA 
phosphorylation of LC3 could suppress autophagosome formation since there would be a 
reduction in its interaction with cargo, thus reducing the signal to form autophagosomes. In the 
case of LRRK2 or even MPP+, this could allow the cell to maintain some level of homeostasis 
through slightly dysfunctional mitochondria as opposed to losing all mitochondrial function by 
degrading them. Interestingly, this selective nature of cargo recognition could allow the cell to 
execute basal autophagy without excessively degrading cytoplasmic components and 
outstripping the biosynthetic capacities of the cell. 
In addition to its known roles in autophagy and microtubule dynamics, new interacting 
proteins that expand upon the known functions of LC3 have been identified in this study. In 
addition to its role in membrane trafficking as part of the autophagy pathway, clathrin and AP2 
have been identified as new interacting proteins that display differential binding affinity based on 
LC3 phosphorylation status. Clathrin and AP2 play roles in membrane trafficking in endocytosis 
and protein transport from the Golgi apparatus96, 97. This interaction between clathrin, AP2, and 
LC3 raises at least three intriguing possibilities. First, this interaction could be one mechanism 
through which autophagosomes acquire lipids for the expansion of autophagosomes. Clathrin-
coated pits form during endocytosis to pinch off portions of the plasma membrane97. The recent 
observation that autophagosomes can utilize plasma membrane98 as one source of lipids for 
autophagosomes supports this theory where endosomal machinery can interface with autophagy 
machinery to generate autophagosomes from plasma membrane lipids.  
Second, LC3 could interact with clathrin or AP2 to mediate autophagocytosis of 
endosomes or even intracellular vesicles. Numerous studies have observed the formation of 
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multivesicular bodies during autophagy induction99. Multivesicular bodies contain many 
membrane-bound vacuoles within an endosome, which arise due to the engulfment of vesicles 
and other endosomes99. Although further investigation is required, the interaction between LC3 
and clathrin could underlie the formation of these multivesicular bodies or the interactions 
between multivesicular bodies and autophagosomes as yet another link between endocytosis and 
autophagy.  
Finally, these interactions could imply that LC3 plays a role in membrane trafficking 
outside of autophagy. The membrane extension, curvature, closure, and tethering functions 
attributed to LC3 could easily be co-opted between multiple membrane trafficking systems. 
Having one protein involved in multiple membrane trafficking pathways could allow the cell to 
integrate the regulations of these pathways via post-translational modifications for example. 
Sequestered cargo during endocytosis could then be directly targeted for degradation rather than 
having to be processed by the recycling endosome.  
Similar to the interactions between LC3 and clathrin or AP2, phosphorylation status of 
LC3 also affects the interaction between LC3 and members of the fatty acid beta-oxidation 
pathway, HADHA and HADHB (Fig. 16). These enzymes are located within the mitochondria or 
cytoplasm and regulate the beta-oxidation of fatty acids100, 101. The discovery of this interaction 
suggests that LC3 could interface with machinery that regulates lipid stores to be utilized for 
autophagosome formation. While additional studies are required, LC3 through its interaction 
with HADHA and HADHB could integrate cellular energy requirements that would induce 
autophagy with the beta-oxidation machinery to generate additional ATP from fatty acid 
degradation. One could hypothesize that LC3 could deliver either beta-oxidation machinery to 
fatty acid in the lysosome or vice versa. This would allow for the degradation of lipids, which 
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accumulate in lysosomal storage diseases if they are not degraded71. Since LC3 is 
dephosphorylated during autophagy induction and dephosphorylated LC3 interacts more 
abundantly with HADHA and HADHB, this supports the idea of beta-oxidation 
involvment/regulation during autophagic degradation. An alternative interpretation is that LC3 
interacts with these proteins during mitophagy, which does not require p62 involvement. The 
reduction in the interaction between the phosphomimetic LC3 and HADHA or HADHB supports 
the idea that LC3 phosphorylation regulates autophagy through cargo recognition, either directly 
or through the adapter protein, p62. Furthermore, the observation that LC3 phosphorylation 
reduces its interaction with p62 and potential lipid sources for autophagosome formation 
provides a possible mechanism to explain why phosphorylated LC3 forms fewer 
autophagosomes (Fig. 14). 
One of the most intriguing observations is the number of interactions detected between 
LC3 and RNA- and DNA-binding proteins. Eight of the thirteen newly identified interactors 
regulate gene expression on the transcriptional or post-transcriptional level (SAFB1, DHX9, 
RBMX, TRA2B, ROA2, THOC4, SFRS9, and SFRS3). These results suggest that LC3 might 
play a role in the regulation of gene expression. This could be another mechanism similar to 
mTOR59, that allows the cell to balance biosynthesis and degradation through the same protein. 
While more investigation is required, LC3 does possess a putative nuclear export sequence, 
providing additional support for this hypothesis. 
Many studies have linked autophagy induction to DNA damage, and while the 
mechanisms are poorly understood, the observation that PARP-1 interacts with LC3 (Fig. 16) 
and the presence of a putative ATM phosphorylation site (Table 4) provide two interesting ways 
that DNA damage could interface with the autophagy machinery. Upon single strand or double 
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strand DNA breaks or DNA base lesions, PARP-1 becomes activated and generates chains of 
poly-ADP-ribose102. It is hypothesized that PARP-1 can also poly-ADP-ribosylate proteins as a 
signaling mechanism to alter protein function, similar to ubiquitination. While poly-ADP-
ribosylation is a relatively new idea to cell signaling, LC3 modification could provide a direct 
link between autophagy and DNA damage. The generation of poly-ADP-ribose from NAD+ 
during DNA damage also creates a high-energy demand on the cell103. Unsurprisingly, this 
increased energy demand would induce autophagy, similar to nutrient deprivation, as a means to 
produce more energy. DNA damage also activates ATM, which then phosphorylates its 
substrates. Although the mechanism remains to be elucidated, LC3 could be a target of ATM, 
providing one more link between autophagy and DNA damage. Whether through direct signaling 
or bioenergetic demands, this interaction suggests yet another new function for LC3 in the 
regulation of cellular homeostasis. 
5.3 ALTERNATIVE NEUROPROTECTIVE MECHANISMS FOR PKA 
While this study has shown that PKA phosphorylation of LC3 is sufficient to prevent mutant 
LRRK2-induced neurite shortening, numerous other targets of PKA have been identified. PKA 
also phosphorylates Atg13 and Atg1 in yeast as an additional mechanism to suppress 
autophagy81. Since mutant LRRK2 induces a non-canonical form of autophagy, it would be 
interesting to investigate whether PKA phosphorylated Atg13 or Atg1 is able to suppress 
autophagy and restore neurite length in neurons expressing mutant LRRK2. This could elucidate 
whether Atg13 or Atg1 regulates canonical and non-canonical autophagy, similar to LC3, or if it 
only regulates canonical autophagy, similar to beclin-1 and the class III PI3K. 
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Besides autophagy regulation, PKA also affects mitochondrial biology through 
transcriptional and post-translational mechanisms104-106. PKA phosphorylates CREB, which 
translocates to the nucleus and mitochondria to increase the transcription of targeted genes106. 
CREB translocation to the nucleus increases the expression of prosurvival factors, such as 
BDNF75. It also coordinates the transcription of mitochondrial and nuclear genes encoding 
subunits of mitochondrial respiration complexes106. A more direct mechanism, however, is the 
PKA mediated phosphorylation of VDAC104. Phosphorylation of VDAC has two known 
functions: first, it inhibits the release of cytochrome c, preventing apoptosis, and second, it 
allows for increased mitochondrial sequestration of calcium104. Activation of PKA has also been 
reported to inhibit mitochondrial permeability transition, which results from calcium overload105.  
In addition to mitochondrial function, PKA regulates mitochondrial dynamics through the 
phosphorylation of Drp1107, 108. PKA mediated phosphorylation of Drp1 inhibits mitochondrial 
fission, allowing for the maintenance of mitochondrial networks, which is thought to increase 
mitochondrial function107, 108. One mechanism underlying this increased mitochondrial function 
is through the diluting of mutations in the mitochondrial genome or defective proteins. In 
conjunction with its effects on mitochondrial function, the enhanced maintenance of 
mitochondrial networks suggests that PKA activation increases the overall health of the 
population of mitochondria in a cell. By enhancing neuronal survival and mitochondrial function, 
PKA could restore mitochondrial and calcium homeostasis, which are lost in neurons expressing 
mutant LRRK2. 
While the increase in mitochondrial function induced by PKA activation could increase 
calcium-buffering capacity, PKA has also been shown to regulate voltage-gated calcium 
channels and glutamate receptors79, 109-111. A majority of studies have found that PKA activation 
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potentiates calcium influx through n-methyl-d-asparate receptor, as well as the release of calcium 
via ryanodine receptors on the endoplasmic reticulum109, 112. Moreover, PKA phosphorylation of 
voltage-gated calcium channels enhances the influx of calcium110, 111. With the exception of one 
study using immortalized hypothalamic neurons113, PKA appears to increase intracellular 
calcium through a number of different receptors and calcium channels. Together, these studies 
suggest that it is unlikely that PKA would restore calcium homeostasis by reducing its influx. 
However, BDNF, a downstream target of PKA, increases the expression of calbindin, which can 
sequester calcium114. Although PKA does not directly suppress increases in intracellular calcium, 
it could induce compensatory mechanisms, such as increased calbindin expression or 
mitochondrial function, to enhance the calcium buffering of the cell. Overall, PKA regulation of 
mitochondrial homeostasis and enhanced calcium buffering could underlie additional 
mechanisms that complement the suppression of autophagy through LC3 phosphorylation, 
providing multiple modes of protection against mutant LRRK2 induced degeneration. 
5.4 MECHANISMS OF PINK1-MEDIATED NEUROPROTECTION 
PINK1 deficiency causes mitochondrial dysfunction and fragmentation, increased ROS 
production, and cell death25-30. Overexpression of PINK1 reverses these observations and even 
protects against H2O2, MPTP/MPP+, 6-hydroxydopamine, and staurosporine25, 34, 35. PINK1 also 
protects against mutant LRRK2 induced injury (Fig. 6). Part of this protection can be attributed 
to the ability of PINK1 to restore mitochondrial homeostasis, since mutant LRRK2 causes 
mitochondrial dysfunction leading to degradation.  
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In addition, PINK1 levels regulate the phosphorylation status of two proteins, Drp1 and 
LC3, that play roles in mitochondrial fission and autophagy, which combine during the process 
of mitophagy (Fig. 7). Although neither protein is a direct target of PINK1, these observations 
agree with previous studies that PINK1 enhances mitochondrial networks and suppresses 
autophagy. There are two possible interpretations of these results: 1) PINK1 acts to suppress 
mitophagy, or 2) PINK1 acts to enhance mitochondrial homeostasis, which reduces the need for 
mitophagy. The second theory seems to be more applicable since PINK1 overexpression leads to 
healthy mitochondria concurrent with a reduction in autophagy. If PINK1 solely suppressed 
autophagy and fission, then the mitochondria would not be degraded and would become 
unhealthy over time unless PINK1 was directly acting upon the mitochondria. Since the 
mitochondria do not appear sickly during PINK1 overexpression25, one would conclude that the 
reduction in autophagy could be attributed to an increase in mitochondrial homeostasis. 
Therefore, it would appear that enhanced mitochondrial homeostasis would signal for the cell to 
suppress fission and autophagy, as indicated by the increase in Drp1 and LC3 phosphorylation. 
These results indicate that the phospho-regulation of these proteins is downstream of and 
dependent on, but indirect from PINK1. 
Based on the PINK1 interaction data, new interacting proteins have been that regulate 
mitochondrial function and therefore fit into a model whereby PINK1 affects mitochondrial 
homeostasis upstream of fission and autophagy machinery. Coupled with a previous finding that 
LRRK2 interacts with ADT and VDAC91, the interaction between PINK1, VDAC, and ADT2 
raises the possibility of converging substrates for these PD genes. Although further investigation 
is required, differential phosphorylation by PINK1 and LRRK2 could explain how these proteins 
oppose each other and how mutations in two different proteins can cause PD. ADT2 is one of 
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three family members that regulate the uptake of ADP into the matrix and release of ATP into 
the cytosol115. By modulating the levels of mitochondrial ADP, ADT2 can directly affect ATP 
production. For example, during times of high-energy demand, the exchange of mitochondrial 
ATP for cytosolic ADP increases to allow for faster production of ATP to meet cellular 
demands115. A deficit in calcium buffering is one instance for elevated energy demand11. ATP 
produced during high levels of intracellular calcium is utilized to extrude or sequester calcium 
via the calcium ATPases8. By binding to and affecting the phosphorylation status of ADT2, 
PINK1 can modulate ATP production and indirectly, affect calcium buffering and cell death. 
Since PINK1 status inversely correlated with ADT2 phosphorylation status, this regulatory step 
must be indirect (Fig. 23). 
Although indirect regulation of ADT2 phosphorylation was detected with PINK1 
overexpression, an increase in VDAC phosphorylation was observed in PINK1 overexpressing 
cells (Fig. 23). VDAC is a channel that spans the outer mitochondrial and regulates the 
conductance of ions and metabolites into and out of the mitochondria116. VDAC has been 
directly implicated in mitochondrial calcium buffering as a calcium selective channel when the 
pore is closed12, 116. Interestingly, VDAC closure allows calcium to enter the mitochondrial, but 
prevents cytochrome c release116, suggesting that pore closure could enable mitochondria to 
sequester more calcium without overload-induced apoptosis. Moreover, phosphorylation of 
VDAC has been associated with pore closure104, suggesting that PINK1 induced VDAC 
phosphorylation could be another mechanism through which it regulates mitochondrial function 
and calcium homeostasis. Further investigation will be required to determine if PINK1 directly 
phosphorylates VDAC, and if so, at which site and how this phosphorylation affects VDAC 
function. 
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The observations that PINK1 interacts with and/or regulates the phosphorylation status of 
ADT2 and VDAC indicates that PINK1 could perturb the mitochondrial permeability transition 
and prevent cell death. In support of this theory, a previous study has shown that PINK1 reduces 
cytochrome c release in response to apoptotic stimuli34. This study suggests that by interacting 
with two components of the permeability transition pore, ADT2 and VDAC, PINK1 could 
directly regulate mitochondrial polarization. Through phosphorylation of VDAC, PINK1 could 
even cause direct pore closure as one mechanism that reduces the release of cytochrome c. 
Combined with previous studies, these results suggest that PINK1 acts to maintain mitochondrial 
homeostasis by regulating the flow of ions and metabolites through the mitochondria or by 
indirectly regulating mitochondrial dynamics (fusion/fission/trafficking) or autophagy. Through 
its affects at the mitochondria, PINK1 could maintain neuronal homeostasis via roles in calcium 
buffering and suppressing apoptosis. 
5.5 PINK1 MUTATIONS AS CAUSE FOR DISEASE: A HYPOTHESIS 
PINK1 deficiency in cultured cells results in decreased mitochondrial function, increased ROS 
production, deficits in calcium buffering, and increased cell death25-30. In PINK1-/- mice, the 
phenotype is less severe. There is no neurodegeneration or changes in mitochondrial content, but 
the animals display a decrease in mitochondrial function accompanied by a minor deficit in 
synaptic plasticity and evoked dopamine release27, 31. The discrepancies between cell culture and 
mouse models indicate that PD caused by PINK1 mutations may be more complex than simply 
loss of function. The lack of a degenerative phenotype in mice could suggest an increase in 
compensatory mechanisms that is absent in cultured cells. There is currently a dearth of studies 
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investigating the roles of PINK1 mutations in neurobiology, as all mutations have been assumed 
to cause loss of PINK1 function. One interesting possibility that has received little attention is 
whether loss of kinase activity could lead to a dominant negative PINK1, which leads to human 
disease. This could explain the meager phenotype in PINK1-/- mice; however, re-expression of 
mutant PINK1 in a PINK1 null background has yet to be reported. 
PINK1 levels mediate the phosphorylation of TRAP1, ADT2, and VDAC. While the 
specific effects of phosphorylation on these proteins have yet to be determined, all three have 
been implicated in suppressing mitochondrial stress and cell death. Since many PINK1 mutations 
decrease its kinase activity, one mechanism leading to disease could be the loss of PINK1 
regulation of TRAP1, ADT2, and VDAC. Through the phospho-regulation of these proteins, 
PINK1 is poised to modulate cellular oxidative stress levels via TRAP1 and calcium buffering 
and metabolism via ADT2 and VDAC. When this regulation is lost due to PINK1 mutations, 
cells would experience elevated ROS levels, decreased mitochondrial function, deficits in 
calcium buffering, and increased cell death, as previously reported in PINK1 knockdown studies. 
While the likelihood that PINK1 has other yet-to-be-identified substrates cannot be dismissed, 
regulation of TRAP1, ADT2, and VDAC could explain the neuroprotective effects of PINK1 
overexpression and the deleterious effects of PINK1 deficiency. Although the mechanisms 
require further investigation, many lines of evidence support a model in which PINK1 mutations 
that reduce kinase activity lead to familial PD. 
As previously mentioned, another theory is that mutant PINK1 could act as a dominant 
negative molecule. The observation that patients with a heterozygous mutation in PINK1 have 
altered mitochondrial membrane potentials, nigrostriatal dysfunction, and are at risk for a late-
onset form of PD would support a dominant negative role for this mutation since the mutant is 
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competing with wild type PINK1 in these patients117, 118. Moreover, this study has found that 
mutant PINK1 binds more heavily to PINK1 interacting proteins via immunoprecipitation (Fig. 
22). The engineered kinase dead K219M mutation in PINK1 always interacted more abundantly 
with interacting proteins as compared to wild type PINK1 (Fig. 22A). Although the effects of the 
L289P mutation were only evaluated in an immunoprecipitation with ADT2, it would be 
hypothesized that this mutation would have similar effects on the binding with other proteins. 
With a 2- to 3-fold increase in binding, PINK1 mutants could efficiently possess a dominant 
negative role; however, more in depth studies will be required. This possible dominant negative 
function could perturb intracellular signaling pathways that regulate mitochondrial homeostasis 
and cellular homeostasis through the disruption of chaperone functions or through the 
mitochondrial exchange of ATP and ADP. These observations could explain how PINK1 
mutations that do not disrupt kinase activity could still cause PD. Moreover, dominant negative 
function of PINK1 mutants would explain why PINK1-/- and PINK1 knockdown animals show 
no signs of degeneration27, 31, 119. It would not be uncommon for mutations that have different 
effects at the molecular level to produce similar effects at the cellular level, the variety of 
mutations in LRRK2 provide just one example. Overall, mutations in PINK1 could cause PD via 
the dysregulation of mitochondrial homeostasis through aberrant or insufficient regulation of 
ADT2 or VDAC. 
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6.0  CONCLUSIONS 
In conclusion, this project has identified a new pathway linking LRRK2, PINK1, and PKA to the 
regulation of mitochondrial degradation via autophagy and neurite shortening. Mutations in 
LRRK2 and PINK1 lead to neuronal injury through converging mechanisms. Mutations in 
LRRK2 disrupted intracellular calcium homeostasis, which led to mitochondrial dysfunction and 
degradation by autophagy. Restoration of calcium homeostasis through calcium chelation or 
inhibition of voltage-gated calcium channels presented an early instance for intervention that 
prevented mitochondrial dysfunction and degradation and neurite shortening. Mutant PINK1 is 
hypothesized to cause direct mitochondrial dysfunction through aberrant interactions with ADT2 
or VDAC. Direct inhibition of autophagy through PKA-mediated LC3 phosphorylation reduced 
the neurite shortening. Similarly, expression of wild type PINK1, which enhances mitochondrial 
homeostasis, prevented the mitochondrial degradation and neurite shortening, potentially 
downstream of the calcium imbalance. This study indicates that LRRK2, PINK1, and PKA 
regulate mitochondrial function through distinct, yet converging pathways. Based on these 
observations, therapeutic interventions aimed at maintaining mitochondrial homeostasis by 
modulating the autophagy pathway or enhancing calcium buffering represents novel targets for 
the development of new treatments for PD. 
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Figure 24: Summary Figure. 
Mutant LRRK2 causes an increase in intracellular calcium due to a deficit in calcium buffering. As the 
mitochondrial attempt to buffer the calcium, the lose mitochondrial membrane potential. Depolarized mitochondrial 
are then degraded through autophagy, and the neurites, devoid of mitochondrial support retract. PKA suppresses the 
mutant LRRK2 phenotype by inhibiting autophagy through the phosphorylation of LC3, which reduces its 
interaction with the cargo adapter, p62. Inset: The phosphorylation of LC3 at S12 negatively regulates its interaction 
with endocytosis and fatty acid degradation machinery. Independent of S12 phosphorylation, LC3 also interacts with 
the DNA damage pathway, possibly to coordinate the response to cellular stress, and the RNA processing machinery 
to balance biosynthesis with degradation. PINK1 acts upstream of PKA by regulating mitochondrial function. This 




7.0  FUTURE PERSPECTIVES 
7.1 IDENTIFYING THE LRRK2 SIGNALING PATHWAY 
As previously mentioned, LRRK2 has been shown to interact with components of the 
cytoskeleton, endocytosis proteins, and the proteins that regulate protein synthesis, but 
determining how mutations in LRRK2 affect calcium homeostasis requires further investigation. 
In order to understand how LRRK2 mutants modulate calcium buffering, future studies will 
utilize immunoprecipitation of LRRK2 to identify binding partners under depolarized and non-
depolarized conditions. Similar to the previous studies with PINK1 in this project, non-biased 
proteomic approaches will be used to identify novel LRRK2 interactors, and targeted strategies 
will be used to determine if LRRK2 interacts directly with proteins that regulate calcium 
homeostasis. 
Two-dimensional gel analysis in the presence of LRRK2 mutants will be used to identify 
phospho-proteins regulated by LRRK2. Using this technique, the phosphorylation status of 
calcium buffering proteins identified through immunoprecipitations will be assessed. In the event 
that LRRK2 does not directly interact with calcium-buffering proteins, differentially 
phosphorylated proteins will be identified from 2D gels in the presence or absense of mutant 
LRRK2. Combined, these non-biased- and targeted-proteomics techniques allow for the 
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identification of proteins that comprise the LRRK2 signaling pathway, which will provide 
further insight into PD as well as new proteins to investigate for roles in disease pathogenesis.  
These future studies share the pitfalls of using an over-expressed, tagged LRRK2 protein. 
Although over-expressed wild type LRRK2 will be used as a control for overexpression for all 
the studies, a possibility exists that the identified interactions may not occur endogenously. To 
overcome this pitfall, all identified interactions can be verified utilizing a knock-in technique by 
transfecting LRRK2 mutants or wild type into neurons from LRRK2-/- mice. Since the 
interaction between most kinases and substrates is very transient, and therefore, difficult to 
observe, another pitfall could be the lack of identifying LRRK2 substrates via 
immunoprecipitations. To overcome this problem, future studies will also utilize 2D gel analysis 
to look for differentially phosphorylated proteins in the presence of mutant LRRK2. After 
LRRK2 substrates and interacting proteins are identified, the effects of these interactions will be 
assessed at the cellular and whole animal level with respect to autophagy regulation, 
mitochondrial homeostasis, and calcium buffering. 
Since this project has discovered that LRRK2 mutations elicit a deficit in calcium 
buffering, future calcium-imaging studies will investigate the roles of the endoplasmic reticulum, 
the mitochondria, and plasma membrane ATPases to determine if mutant LRRK2 affects 
calcium homeostasis by disrupting one of these calcium-buffering mechanisms. The level of 
calcium in the mitochondria and endoplasmic reticulum will be analyzed in the presence or 
absence of mutant LRRK2. Determining which compartments become dysfunctional in the 
presence of mutant LRRK2 will provide a subcellular localization, in which to further probe for 
LRRK2 substrates. These studies will provide vital information regarding how LRRK2 mutations 
directly affect calcium homeostasis and the subsequent neurodegeneration. 
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7.2 UNDERSTANDING THE PINK1 NETWORK 
In this project, novel PINK1 interactors have been identified in preliminary experiments. To 
further validate the interaction between PINK1 and ADT2, future studies will utilize 
immunoprecipitations for ADT2-GFP followed by immunoblotting for endogenous PINK1. To 
further determine if ADT2 or VDAC1 are PINK1 substrates, 2D immunoblots will be performed 
in the presence or absence of PINK1 WT, L489P, or K219M. Future studies will also determine 
if PINK1 directly phosphorylates either of these proteins. If PINK1 phosphorylates either 
protein, either directly or indirectly, mass spectrometry and site-directed mutagenesis will be 
utilized to confirm the identification of the phosphorylation site. Additional studies would 
investigate the biological functions of these phosphorylation sites on mitochondrial homeostasis, 
calcium buffering, and protecting from mutant LRRK2-induced neurodegeneration. These 
studies will investigate the potential PINK1 substrates; furthermore, these studies may uncover 
the mechanism(s) responsible for PD associated with PINK1 mutations. 
In the event that PINK1 does not phosphorylate these newly identified interactors, 
bioinformatics will be used to identify potential kinases capable of phosphorylating the identified 
residues, whose phosphorylation status is modulated by PINK1. In this case, additional studies 
would be focused on how PINK1 regulates these sites, what other kinases are involved, and how 
this network affects mitochondrial homeostasis and neurodegeneration.  
 81 
7.3 ELUCIDATING THE ROLE OF LC3 PHOSPHORYLATION 
While the preliminary results suggest that LC3 phosphorylation modulates its interaction with 
endosomal machinery and the autophagy cargo adapter protein, p62, these interactions require 
further investigation. First, immunoblot confirmation of the interactions is required to better 
assess the affects of LC3 phosphorylation on these interactions. To further validate and 
investigate the function of LC3 phosphorylation, future studies will use site-directed mutagenesis 
to disrupt these interactions to determine the biological effects of LC3-p62, -clathrin, and -AP2 
interactions. Future studies should also aim at determining which species of LC3, LC3-I or LC3-
II, binds to the identified binding partners since this information would greatly impact the 
understanding of LC3 function in each of these interactions. For example, does the endosomal 
machinery interaction with LC3 as a component of the autophagy pathway or as a component of 
the cytoskeleton? This data could provide insight into why LC3 phosphorylation reduces its 
incorporation into autophagosomes and provides protection against toxin and genetic models of 
PD. 
In addition to p62, other autophagy adapter proteins, such as NBR1, should be 
investigated to determine whether phosphorylation of LC3 modulates all interactions with 
adapter proteins, or if it provides more specific regulation of LC3 function. These data would 
answer the question of whether LC3 phosphorylation suppresses autophagy induction or simply 
alters cargo recognition. Furthermore, LC3 phosphorylation appears to cause variable shifts 
when comparing either tumor cells to normal cells or human cells to murine cells. This is evident 
in the increase in apparent molecular weight of phospho-LC3 (~20kDa; greater than LC3-I) in 
human tumor cell lines versus murine neurons (~16kDa; identical to LC3-I). Additional studies 
will investigate why this apparent size difference exists by probing for additional post-
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translational modifications that may cause this shift in molecular weight. Isoform differences 
between the cell types will also be investigated to determine if differential expression of isoforms 
could be the underlying reason for this shift in the apparent molecular weight, since LC3a and b 
have been detected at ~16kDa and LC3c at ~18kDa. These studies should provide more insight 
in the regulation of autophagy by LC3, focusing on the post-translational modification and 
protein-protein interactions that regulate this key autophagy protein. 
In summary, the future studies will extend the preliminary discoveries of this project to 
elucidate the cellular and molecular mechanisms underlying neurodegeneration caused by 
LRRK2 mutations. Furthermore, they will investigate the PINK1 signaling pathway to 
understand how it modulates mitochondrial homeostasis and function and to identify 
downstream targets that may present points for therapeutic intervention. Finally, the effects of 
post-translational modifications on LC3 will be further investigated. The findings from these 
studies will illustrate how LC3 is regulated and how it regulates intracellular events that affect 
neurodegeneration both within and beyond the autophagy pathway. The preliminary findings 
reported from this project will provide a basis for the discovery of the molecular mechanisms 
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